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The combination of AMD3100 and low-dose FK506 has been shown to accelerate 
wound healing in vivo. Though AMD3100 is known to work by releasing hematopoietic 
stem cells into circulation, the mechanism of FK506 in this setting has remained unknown. 
In this study, we investigated the activities of FK506 in human cells and a diabetic-rat 
wound model using a non-immunosuppressive FK506 analog named FKVP. While FKVP 
was incapable of inhibiting calcineurin, wound healing enhancement with AMD3100 was 
unaffected. Further study showed that both FK506 and FKVP activate BMP signaling in 
multiple cell types through FKBP12 antagonism. Furthermore, selective inhibition of BMP 
signaling abolished stem cell recruitment and wound healing enhancement by combination 
treatment. These results shed new light on the mechanism of action of FK506 in BMP-
mediated acceleration of wound healing, and raised the possibility that less toxic non-
immunosuppressive FKBP ligands such as FKVP can replace FK506 as novel leads for 
wound healing. Moreover, new synthetic techniques and in vitro screening systems have 
translated into a methodology for the production and identification of additional non-
immunosuppressive analogs to be tested in vivo. Further study shows that FKBP12 protein 
degradation can be chemically-induced using either a specialized FK506 analog or SNAP 
protein substrate. This technique generated our most potent BMP-activator, as well as a 
new method for identifying protein-protein interactions in live cells. 
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Wounding due to accidents, diseases, and armed conflict is one of the most common 
medical problems. Cost of care for chronic, non-healing wounds associated with severe 
burns and diseases such as diabetes has been estimated to exceed 50 billion dollars per 
year (Fife et al., 2012). Chronic wounds make the human body more susceptible to 
infection, increasing the risk of acquiring opportunistic pathogens that can lead to sepsis. 
Thus, accelerating wound healing (WH) can reduce the risk of infection, improving the 
mortality and morbidity rates of wounded patients. However, there are limited options to 
shorten wound healing, calling for development of new therapies. 
We have previously reported the discovery of a synergistic drug combination for the 
acceleration of cutaneous WH (Fig. 1.1, Lin et al., 2014) and the induction of long-term 
allograft survival through host repopulation (Okabayashi et al., 2011, Hu et al., 2016, 
Cameron et al., 2016). The combination of two FDA-approved drugs, Tacrolimus 
(FK506) and Plerixafor (AMD3100), reduced the complete healing time by 25% in mice 
with four circular full-thickness excisional wounds, which is unprecedented by existing 
therapeutic modalities. To date, there has not been an approved small-molecule treatment 
for wound healing. This leaves a large subset of patients that may not respond to current 





Figure 1.1: Previous work in the lab of Dr. Zhaoli Sun uncovered a combination 
treatment for acceleration of wound healing. In 2014, the Sun lab published an article 
in the Journal of Investigative Dermatology showing that concomitant AMD3100 and low-
dose Tacrolimus accelerated wound healing in mice by 25% (Lin et al, 2014). (a) Early 
healing. Representative photographs of wounds in mice (n=6) showing striking differences 
beginning at day 5. (b) Quantitative analysis of wound closure in mice (n=6). *P<0.05. 
 
Accelerated WH is accompanied by the mobilization of bone marrow (BM)-
derived stem cells (CD133, CD34, and cKit) and the recruitment of CD133 stem cells 
into wound sites,  as well as augmented stromal derived factor 1 (SDF-1), fibroblast 
growth factor (FGF), and vascular endothelial growth factor (VEGF) release in 
granulation tissues (Lin et al., 2014). The underlying molecular mechanism by which the 





AMD3100 is a selective antagonist of the chemokine receptor CXCR4 (Hatse et 
al., 2002) and has been used clinically to drive hematopoietic stem cells (HSCs) out of 
the bone marrow (BM) into the peripheral blood (Liles et al., 2003) where they can be 
recovered and preserved until the completion of ablative irradiation and/or chemotherapy. 
In addition to HSCs, the injection of AMD3100 augmented the mobilization of BM 
derived endothelial progenitor cells (EPCs), which are associated with more rapid 
neovascularization and functional recovery after myocardial infarction in mice (Jujo et 
al., 2010; Balaji et al., 2013). However, increased number of circulating stem cells by 
AMD3100 treatment alone exhibited only slightly faster healing due to reduced 
recruitment in wound sites (Lin et al., 2014).  
In contrast to AMD3100, the precise role played by low-dose FK506 in the 
combination treatment (AF) has remained a mystery. FK506, a macrolide produced by 
the bacteria Streptomyces tsukubaensis, is an immunosuppressant widely used for 
prevention of transplant rejection as well as treatment of certain autoimmune disorders 
(Tanaka et al., 1987; Fung et al., 2004). The underlying mechanism for the 
immunosuppressive activity of FK506 has been well established. At the cellular level, 
FK506 inhibits the activation of T helper cells. At the pathway level, it blocks the 
intracellular signal transduction emanating from the T cell receptor leading to 
transcriptional activation of IL-2 and other cytokine genes. At the molecular level, it 
binds to FKBP12 and other members of the FKBP family before the binary FKBP-FK506 
complex associates with and inhibits the activity of the protein phosphatase activity of 
calcineurin, preventing calcium-dependent dephosphorylation of the nuclear factor of 
4 
 
activated T-cells (NFAT) (Figure 1.2) (Liu et al., 1991; Griffith et al., 1995; Kissinger et 
al., 1995).  
 
 
Figure 1.2: The NFAT Pathway is inhibited by FK506. Schematic depicting 
FKBP12’s use of FK506 to inhibit calcineurin-mediated dephosphorylation of NFAT. 
Calcineurin is activated through both T-cell receptor (TCR) activation and calcium flux. 
 
A possible underlying mechanism for FK506 in WH is through inhibition of 
calcineurin. However, it has been shown that topical FK506 has a detrimental effect on 
WH (Schäffer et al., 1998). Furthermore, we have shown that animals treated with low-
dose FK506 (0.1 mg/kg) alone exhibited slightly faster healing compared to the saline 
control group, but the standard dose of FK506 (1 mg/kg) for immunosuppression delayed 
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healing time, leaving unanswered the question of whether calcineurin inhibition is 
responsible for the effect of FK506 on WH. 
Further reports have shown alternate biological activities for FK506, some of 
which are not related to calcineurin inhibition. Of particular interest are modulation of 
Bone Morphogenic Protein (BMP) signaling and neuroregenerative capabilities, both of 
which are suggested to work through FKBP binding. 
FK506 competes with FKBP12 for association with TGF-β, ryanodine, and 
inositol trisphosphate (IP3) receptors.  However, there is limited evidence that 
competition alone is enough to activate these receptors in the absence of endogenous 
signal. Calcium flux activity by IP3 receptors was only shown to be enhanced in the 
presence of exogenous IP3 (in lipid microsomes) (Cameron, 1995). Further reports state 
that an FK506 analog was unable to activate a luciferase reporter driven by TGF-β 
receptor (in mink lung cells) activation unless exogenous TGF-β protein was added. 
Additionally, Spiekerkoetter et al. showed that FK506 could not activate a TGF-β 
luciferase reporter in C2C12 musculoskeletal cells (Spiekerkoetter et al., 2013). It should 
be recognized that FK506 was found to upregulate the TGF-β co-receptor endoglin 
through BMP activation (Albiñana et al., 2011), possibly increasing sensitivity towards 
endogenous TGF-β protein. 
In general, the propensity of FK506 and its analogs to modulate calcium signaling 
through ryanodine and IP3 should be the greatest concern in cardiac/vascular muscle cell 
contractility. However, Spiekerkoetter et al. demonstrated that low-dose FK506 treatment 
did not adversely affect blood pressure in mice (over 3 week treatment period) 
(Spiekerkoetter et al., 2013). Recent clinical trials have also highlighted the human 
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tolerability of low-dose (sub-immunosuppressive) FK506 for the treatment of pulmonary 
arterial hypertension (Spiekerkoetter et al., 2017). 
FKBP12 has been shown to inhibit BMP type 1 receptor activation (Wang et al., 
1996). Importantly, this interaction could be relieved by FK506 (Spiekerkoetter et al., 
2013), causing downstream signaling changes and BMP-dependent phenotypic changes 
in endothelial cells. BMP signaling has not yet been directly linked to any stage of wound 
healing, although it has been reported that epithelial cells down-regulate BMP receptors 
in response to injury (Lewis et al., 2014). Conversely, it has been recently reported that 
enhanced BMP signaling within myofibroblasts may promote scarless wound healing 
(Plikus et al., 2017), suggesting that regeneration of wounded tissue  may be preferred to 
conventional wound healing processes (inflammation, proliferation, remodeling). BMPs 
have been demonstrated to produce a pro-inflammatory phenotype in endothelial cells, 
thereby increasing leukocyte adhesion and SDF-1 secretion (Csiszar et al., 2006; Young 
et al., 2012). Upon activation, BMP receptors phosphorylate and activate the SMAD 
transcription factors 1, 5, and 8. One major target gene of these SMADs is inhibitor of 
differentiation 1 (ID-1), which inhibits transcription of several genes related to 







Figure 1.3: The BMP Pathway is activated by FK506. Schematic depicting FKBP12 as 
a modulator of BMP type 1 receptor activation. Activated receptor kinases phosphorylate 
SMAD1/5/8 transcription factors, causing them to translocate into the nucleus and 
promote expression of ID-1 and other genes. The compound LDN-193189 has been 
shown to inhibit receptor kinase activity, preventing downstream signaling. 
 
Previous studies have examined some of  the downstream effects of BMP receptor 
activation following FK506 treatment, which is accompanied by increases in SMAD1 
and SMAD5 (denoted SMAD1/5) and/or SMAD8 (denoted SMAD1/5/8) 
phosphorylation in skeletal muscle cells (Spiekerkoetter et al., 2013) and human synovial 
stromal (hSSC) cells (Tateishi et al, 2007). Additionally, increases were observed in 
MAPKK phosphorylation and ID-1 expression, and the activity of FK506 was sufficient 
to rescue endothelial dysfunction in mice induced by a conditional BMP receptor type 2 
(BMPR2) knockout (Spiekerkoetter et al., 2013).  It has been reported that FK506 
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upregulated phosphorylation of SMADs downstream of the TGF-β signaling pathway 
(SMAD 2 and 3) in smooth muscle cells (Giordano et al Cardiovasc Res. 2008; Bennet et 
al. J Clin Med. 2016). However, downstream transcriptional activity was only seen in the 
presence of supplemented exogenous TGF-β (Spiekerkoetter et al., 2013; Wang et al., 
1996). In another study, it was shown that FK506 increased expression of the TGF-β type 
3 co-receptor endoglin, and stimulated both migratory and angiogenic activity of 
endothelial cells (Albiñana et al., 2011). 
Together, these observations raised the possibility that FK506 may exert its WH 
effect through FKBP12 alone, independent of calcineurin inhibition. We hypothesized 
that non-immunosuppressive analogs of FK506 would retain activity in WH, while 
reducing off-target toxicity related to immunosuppression. Active compounds lacking 
immunosuppressive activity presents a valuable opportunity to improve the safety profile 
of this exciting new treatment for wound healing acceleration, especially in 










2. DISCOVERY OF FKVP BY FK506 DERIVATIZATION USING RUTHENIUM-
CATALYZED CROSS METATHESIS 
 
2.1 INTRODUCTION 
 FK506 also known as tacrolimus or fujimycin is a 23-member, macrolide natural 
product derived from the bacterium Streptomyces tsukubaensis (Fig. 2.1). Since 
1994, FK506 has been widely used in the clinic for prevention of allogeneic 
transplant rejection (Tanaka et al., 1997; Fung et al., 2004). 
 
     
Figure 2.1: Structure of FK506. 
 
 It has been shown through crystal structure studies that FKBP12 interacts with 
several proteins in both an inducible (FKBP12-FK506-calcineurin) and non-
inducible (FKBP12-BMPR1) fashion (Griffith et al., 1995, Kissinger et al., 1995, 
Chaikuad et al., 2012). FK506 has shown unique biological activities unrelated to 
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immunosuppression and is currently a lead pre-clinical compound for treating 
diseases such as pulmonary hypertension (Speierkoketter et al, 2013) and bladder 
cancer (Shin et al, 2014). 
 To generate a series of FK506 analogs devoid calcineurin inhibition, we decided 
to employ ruthenium-catalysed cross metathesis (CM). Previous reports have used 
CM to generate non-immunosuppressive FK506 analogs (Clemons et al, 2002; 
Marinec et al., 2009), which modifies the terminal alkene of FK506 on the C39 and 
C40 positions. At this position, steric bulk was shown to prevent calcineurin 
association and inhibition of NFAT transcriptional activity. To determine if 
calcineurin inhibition was required for enhanced healing by the AF combination, we 
designed and synthesized analogs of FK506 by using ruthenium-catalysed cross-
metathesis to fuse different polar moieties to the terminal alkene as a “bump” in the 
effector domain of FK506 (Figure 2.2). We hypothesized that the addition of polar 
groups would not only clash with the hydrophobic binding pocket of calcineurin, 
but also improve solubility. 
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Figure 2.2: Scheme for formation of non-immunosuppressive analogs. Using 
chemistry to append bulky substituents at the C40 terminal alkene of FK506 has 
previously been shown to prevent calcineurin inhibition. 
 
 Additionally, we wanted to explore the use of free phosphoryl moiety in our 
study, yet vinyl-phosphonic acid did not give product in the CM reaction. Therefore, 
we designed a disoproxil-protected phosphonate that would lose its protecting 
groups after cleavage by intracellular esterases. This these groups protect the 
charged phosphate during both CM reaction and cell permeation. 
 Generated analogs were characterized by high-resolution mass spectrometry 
before they were screened in both NFAT reporter and wound healing assays. To 
assist in determining lead candidates for further study, the BMP reporter activation 






Synthesis of FK506 analogs by ruthenium-catalyzed cross metathesis 
 Cross metathesis reactions gave different yields based primarily on chelation 
ability of allylic or vinylic substrates. Nitrogen-containing moieties had the most 
difficulty, with boc or tosylate-salt protection needed for modest yields (Fig. 2.3). 
Conversely, yield of compound 1 did not improve with tosylate-salt protection 
during the CM reaction. Introduction of polar moieties greatly improved 
purification by increasing chromatographic separation from the parent compound 
(FK506). This process proved vital for isolation of compounds on a larger (20-100 
mg) scale.  
Addition of charged phosphonates to FK506 via CM gave no recoverable yields. In 
an attempt to access these interesting moieties, a protected phosphonate was designed 
(compound 4) in the same prodrug-strategy employed by anti-retroviral nucleotide analogs 
such as tenofovir disoproxil. The disoproxil-protected FK506 analog (3) was generated by 
standard CM reaction with a vinyl phosphonate that had been substituted with two 
carbonate-based protecting groups (Houghton et al, 2010). These protecting groups can be 
cleaved by intracellular esterases, producing a charged phosphonate group at the terminal 










Figure 2.3: Synthesis of FK506 analogs by CM. High concentrations of ruthenium 
catalyst allowed for modest yields of most substrates. Reactions with amines required 
tosylate-salt or Boc protection for respectable yields. Synthesis of compound 1 did not 




Figure 2.4: Synthesis scheme of disoproxil-protected phosphonate FK506 analog (3). 
Diethyl vinyl phosphonate (substrate for compound 2) was protected in one step, 
followed by CM to FK506. The esterase-cleavable groups were designed to be 







CM-generated FK506 analogs show variable activity in an NFAT reporter assay 
 In total, nine FK506 analogs were produced and purified. These compounds were 
initially tested for immunosuppressive activity in an NFAT reporter system (Figure 
2.5) (Clemons et al, 2002). Calcineurin activity was measured by the ability of 
compounds to prevent luciferase transcription activated by PMA and ionomycin. 
Known immunosuppressive compounds FK506 and cyclosporine A (CsA) potently 
inhibited luciferase transcription relative to activated, DMSO-treated samples (Fig. 
2.6). Additionally, the FKBP-ligand SLF showed no significant inhibition of the 
reporter at doses under 10 μM.  
 
 
Figure 2.5: Schematic of NFAT reporter activation. PMA/Ionomycin is used to 
activate calcineurin dephosphorylation of NFAT. Subsequent translocation of 
NFAT promotes expression of the luciferase vector. FK506 and its analogs are 
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screened for their ability (or lack thereof) to block luciferase expression and its 
resulting luminescence. 
 
 Of the compounds tested, most were found to have limited or no calcineurin 
inhibition. Compounds 3, 4, and 7 showed immunosuppressive activity (Table 2.1), 
with compound 3 showing the most potent reporter inhibition. This data strongly 
suggests that disoproxil groups on 3 are cleaved upon cellular entry, producing a 
free phosphonate (10) that is accommodated by calcineurin during the FKBP12-
calcineruin interaction. This is also supported in that compound 4 remained non-
active in the assay, as the addition of ethyl groups to the phosphonate is enough to 
block calcineurin inhibition. 
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Figure 2.6: Dose response curves for FK506 and analogs in the NFAT reporter 
assay. Transfected Jurkat cells were activated by PMA/Ionomycin 30 min after 
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compound treatment. Luciferase activity was normalized to activated DMSO control 




Table 2.1: Calculated IC50 values of CM analogs in NFAT reporter assay.    





















CM-generated FK506 analogs activate a BMP reporter assay 
     To further characterize the FK506 analogs, we employed a BMP reporter assay 
(Figure 2.7) (Speierkoketter et al, 2013). After testing C2C12 cells for reporter activity 
(as used in the publication), we found that Jurkat cells produced a better signal-to-noise 
ratio with far lower basal activity. Jurkat cells express all necessary components of 
calcineurin-NFAT, BMP, and CXCR4 signaling pathways, making these cells an 
appropriate model for cell-based assays. 
 
 
Figure 2.7: Schematic of BMP reporter activation. FK506 and its analogs are 
screened for their ability to activate luciferase expression and its resulting 
luminescence. 
 
     All analogs were found capable of activating the BMP reporter with similar potency 
when compared to FK506 (Fig. 2.8). The only exception to this trend was compound 7, 
19 
 
suggesting decreased cellular permeability that aligns with results from NFAT assay (Fig. 
2.6). EC50 values for all compounds (except 7) were in the low nanomolar range, with the 
most potent compound being analog 4 (Table 2.2). Interestingly, calcineurin activity did 
not correlate with BMP activation potential. This finding contradicts findings by 
Speierkoketter and colleagues, who reported that calcineurin inhibition played a role in 
FK506’s activation of BMP signaling. This could be a result of differences in basal BMP 
signaling between Jurkat cells used here (low) and C2C12 mouse musculoskeletal cells 
(high) used in previous work (Speierkoketter et al, 2013). 
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Figure 2.8: EC50 curves determined by relative luciferase activity in the BMP 
reporter assay. Transfected Jurkat cells were treated with indicated compounds for 18 
hours before luciferase measurement. Luciferase activity was normalized to activated 
DMSO control samples. FK506 served as a positive control. 
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Table 2.2: Calculated EC50 values of CM analogs in BMP reporter assay. 


























FK506 analogs show WH enhancement in preliminary in vivo screening 
      To determine the ability of FK506 analogs to promote wound healing acceleration, 
compounds were tested in combination with AMD3100 in a wound-healing assay in SD 
rats. Compounds were dissolved into a formulation of 20% Cremophor in ethanol before 
1:50 dilution into saline (0.1 mg/mL final concentration). Solutions were injected 
subcutaneously on alternating day until wound re-epithelialization. Four full-thickness 
excisions were created by 8 mm surgical punch, and monitored daily until complete 
wound re-epithelialization (Fig. 2.9). FK506 + AMD3100 combination treatment served 
as a positive control. 


















































Figure 2.9: Hits from initial screening of FK506 analogs in wound healing. Three SD 
rats from each treatment group were given four excisional wounds, followed by 
concomitant treatment with AMD3100 every-other-day until wound closure (re-
epithelialization). FK506 served as a positive control. 
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     Four analogs gave significant healing acceleration when compared to saline (Table 
2.3) that was insignificant when compared to FK506, suggesting equal WH activity. Of 
these hits, three analogs were found earlier to have no calcineurin inhibition (Fig. 2.6). 
Moreover, two analogs that gave fastest healing (1 and 4) also performed best in the BMP 
reporter (Fig. 2.8), but had opposite effects in the NFAT reporter. These results strongly 
suggest that wound healing acceleration by FK506 and its analogs is more dependent on 
BMP activation than NFAT inhibition. 
 
Table 2.3: P-values from one-way ANOVA analysis of treatment results. 
Group 1 Group 2 P 
Saline 4+AMD 1.8E-05 
Saline FK506+AMD 0.00064 
Saline 6+AMD 0.00082 
Saline 1+AMD 0.00094 












2.3 MATERIALS AND METHODS 
Chemicals: Research-grade FK506 (>98%) was purchased from APExBIO. Substrates 
and solvents were purchased form MilliporeSigma. Zhan-1b Ruthenium catalyst (CAS: 
918870-76-5) was purchased from STREM Chemicals. 
 
General Analog Synthesis: To a solution of FK506 (100 mg, 0.120 mmol) and 
30mol% Zhan1b catalyst RuCl2[C21H26N2][C12H17NO3S], in 3mL anhydrous DCE 
was added 4-vinylpyridine (14.2 µL, 0.132 mmol) or other reagent (Fig. 2.1). The 
mixture was stirred for 30 s before microwave irradiation at 120 °C for 20 min. The 
mixture was then purified using flash chromatography, preparative-TLC, and/or 
reverse-phase HPLC. Both LC-MS and 1H-NMR experiments were used to confirm 
the new compounds were >95% pure. Product was characterized using high-
resolution MS or 1H-NMR, then dissolved in DMSO or used in formulation for 
animal experiments.  
 
For animal experiments, FKVP powder was dissolved into 80% EtOH/20% Cremophor 
RH60 solution at 5 mg/mL. This stock was diluted 1:50 into saline before subcutaneous 
injection. 
 
Cell Culture and Transfections 
Jurkat (E6.1, ATCC) cells were cultured in RPMI with 10% FBS and 1.5% PennStrep. 
Jurkat cells (1 x 106) were transfected with 10 μg of BRE-Luciferase (kindly provided by 
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Martine Roussel & Peter ten Dijke) or NFAT-Luciferase cDNA (Promega) by 
electroporation (BioRad, square-wave, 250V, 950μF) in 400 μL serum/antibiotic free 
RPMI with 0.5% DMSO. Thirty minutes after transfection, cells were transferred to 
complete RPMI and rested overnight. Before plating, cells were re-suspended in fresh 
media and diluted to 0.5x106 cells/mL. HUVEC cells were cultured in Lonza Endothelial 
cell Growth Medium (EGM-2) and used between passages 3 and 7. All cells were grown 
and assayed at 37 °C with 5% added CO2. 
 
BMP and NFAT Pathway Reporters 
Jurkat cells used for each experiment were transfected at the same time and cultured 
together overnight until plating and treatment the following day. 
Jurkat T cells transfected with BRE-Luc were split into a 96-well plate (80 µL/well of 
0.5x106 cells/mL)) and treated with previously stated compounds (20 μL of 5X stock in 
RPMI, 0.5% DMSO) for 18 hours. Cells were lysed and measured for luminescence 
using a PerkinElmer Microbeta2. Luminescence values were background subtracted 
(lysis buffer + substrate) and normalized to DMSO control values. 
Jurkat T cells transfected with NFAT-Luc were split into a 96-well plate (80 μL/well of 
0.5x106 cells/mL) and treated with indicated compounds (20 μL of 5X stock in RPMI, 
0.5% DMSO) 30 min before activation with PMA/Ionomycin (40nM/1μM). After 6 
hours, wells were lysed and measured for luminescence. FK506 served as positive control 





Calculations were performed using GraphPad Prism 6. Curves were fit using non-linear, 
log(agonist) vs. response (three parameters). 95% confidence intervals of EC50 values are 
reported below. 
 
Declaration of Ethical Animal Care and Use 
Goto-Kakizaki (GK) type-2 diabetic rats obtained from Charles River (Boston, MA) were 
housed in a pathogen-free facility and cared for according to NIH guidelines and a 
protocol approved by the Johns Hopkins University Animal Care and Use Committee 
(ACUC). Both male and female GK rats at age of 4-5 months were used in this study.  
 
In vivo Excisional Wound Model 
Full-thickness wounds were created in the dorsal skin of rats with a sterile disposable 
biopsy punch (8 mm in diameter). The animals were injected subcutaneously with saline, 
AMD3100 (1 mg/kg) plus FK506 (0.1 mg/kg) or AMD3100 (1 mg/kg) plus FKVP (0.1 
mg/kg) immediately after wounding and every other day until complete healing, defined 
as complete re-epithelialization of the wound area. Wounds were evaluated daily 







The one-way analysis of variance (ANOVA) was used to determine the statistically 
difference in wound healing among AF, AF+LDN, Saline and S+LDN groups or between 
AF, AV and Saline groups when comparing days of wound healing. Bonferroni-Holm 
post-hoc procedure was used for p value adjustment. p<0.05 is considered significantly 
different. 
 
2.4 COMPOUND CHARACTERIZATION 
High resolution mass spectrometry for all compounds was performed by UCIC’s mass 
spectrometry facility. Samples were sent dissolved in DMSO. 
 
Figure 2.10: High-resolution mass-spectrometry profile of compound 1.  




Figure 2.11: High-resolution mass-spectrometry profile of compound 2.  













Figure 2.12: High-resolution mass-spectrometry profile of compound 3.  













Figure 2.13: High-resolution mass-spectrometry profile of compound 4.  












Figure 2.14: High-resolution mass-spectrometry profile of compound 5.  











Figure 2.15: High-resolution mass-spectrometry profile of compound 6.  












Figure 2.16: High-resolution mass-spectrometry profile of compound 7.  











Figure 2.17: High-resolution mass-spectrometry profile of compound 8.  













Figure 2.18: High-resolution mass-spectrometry profile of compound 9.  












     Although integration is difficult for these large macrocycles, we can compare the 
spectra to that of FK506. In the 5.5-6.0 ppm range, it can be seen that a multiplet caused 
by the terminal alkene of FK506 is not present in compound 1 (Fig. 2.16). Moreover, 
peaks from 4-vinylpyridine are also seen in compound 1 (8.5 and 7.0ppm). 
Figure 2.19: FKVP structure characterization. 1H-NMR spectra of (A) FKVP and (B) 
FK506 (CDCl3), including detail of 5.5ppm~6.0ppm showing disappearance of terminal 













Our biological analysis of CM-prepared FK506 analogs suggests that FKVP (1) is the 
optimal lead compound for further study into non-immunosuppressive BMP activation 
and wound healing acceleration. While compound 4 showed slightly better BMP 
activation and WH acceleration, its retention of potent calcineurin inhibition makes it 
unfit for future study. Moreover, any increases in WH and BMP activity over the non-
immunosuppressive analog FKVP (1) were insignificant. This suggests that WH 
acceleration is operates through FKBP12, independent of calcineurin inhibition. 
Interestingly, the prodrug form of phosphonate analog 3 showed the strongest calcineurin 
inhibition of all analogs (IC50<1nM), suggesting that addition of free phosphonate (after 
cellular hydrolysis of carbonate groups) to the terminal alkene does not prevent 
calcineurin association. This also suggests that while compound 2 performed well in 
testing, it is a poor translational candidate for fears of phosphonate hydrolysis.  
We began this project by questioning the necessity of calcineurin inhibition in wound 
healing acceleration by AF. Results show that out of the four hits in the wound healing 
screen, three are non-immunosuppressive. This indicates that the calcineurin inhibition 
activity of FK506 is not required for wound healing acceleration by AF. Moreover, trends 
in BMP activation potential and wound healing suggest a correlation that stems through 
FKBP binding alone. 
Conversely, calcineurin has recently been reported to interact with the FKBP12-
BMPR1 axis. This was evidenced by reduced activity of a linear FKBP antagonist 
(Shield-1) in the BMP reporter compared to FK506. Moreover, they showed a small 
increase in activity by a calcineurin inhibitor (cyclosporine A) that does not function 
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through FKBP. While we could not yet rule out the involvement of calcineurin, we show 
here that macrocyclic FK506 analogs activate BMP signaling at nearly the same level, 
regardless of calcineurin inhibition. Our findings suggest analog induced BMP activation 
may only be hampered by reduced cell-permeability, as the poorest performing analog 
had a large amino acid with a free carboxylate at the terminal alkene. This data supports 
the theory that FKBP binding may be the only requirement for BMP activation. Further 
study into the BMP pathway and its activation by FKVP may reveal important clues into 
the mechanism of AF-induced wound healing acceleration. Additionally, through a 
second round of structure-activity relationship studies based on FKVP, we may find 


















3 ACTIVATION OF BMP SIGNALING SYNERGIZES WITH CXCR4 
INHIBITION TO ACELLERATE WOUND HEALING*# 
*This work was completed in collaboration with Dr. Le Qi. 
#LQ performed animal surgery and histology, BP performed synthesis and cell-based assays 
3.1 INTRODUCTION 
In the previous chapter, we reported the discovery of FKVP for non-
immunosuppressive wound healing acceleration. Our results suggest that the calcineurin-
opposed (non-immunosuppressive) FK506 analog not only activates BMP reporter with 
higher potency, it also performs equally well in acceleration of wound healing. However, 
the question still remains as to whether or not the BMP pathway is relevant to wound 
healing. Studies have been inconclusive as to the precise mechanism for BMP activation 
by FK506, and at least one report suggests that calcineurin is required for signaling 
through BMP receptors (Spiekerkoetter et al., 2013). 
In this chapter, we attempt to deconvolute the BMP pathway in regards to activation 
by FK506 and FKVP. Furthermore, we show that BMP receptor activity is intimately 
involved in wound healing in vivo, increasing mobilization and recruitment of stem cells 
at wounded tissues. To further display the power of this treatment, we chose clinically 
relevant Goto-Kakazaki (GK) rats as a model organism to demonstrate the potency of our 
treatment in a diseased model.  GK rats spontaneously develop type-2 diabetes early in 
life, and suffer from many of the same complications as humans including slowed healing 
of wounds. A treatment for accelerated healing of diabetic wounds/ulcers in the clinic 
may significantly decrease co-morbidities associated with this disease, for which no 
small-molecule therapies currently exist. Moreover, these compounds may eventually be 
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used treat chronic, non-healing wounds that are sometimes present in diabetic patients 
with an advanced stage of disease. 
 
3.2 RESULTS 
Characterization of the non-immunosuppressive analog - FKVP 
From our previous study, we identified compound 1 (FKVP) as our lead non-
immunosupressive candidate for BMP and wound healing studies. We assessed the 
cytotoxicity of FKVP and compared it to that of FK506 in both Jurkat T (Fig. 3.1A) and 
primary HUVEC cells (Fig. 3.1B). Like FK506, FKVP did not affect cell viability at 
concentrations up to 10 µM.  
Figure 3.1: FKVP treatment of Jurkat cells does not significantly affect proliferation 
in several cell types. In resazurin-based (A) Jurkat and (B) HUVEC cell viability assays, 
FKVP treatment shows no significant changes after 3 day treatment (compared to DMSO 




To confirm that FKVP retained the ability to bind FKBP, we applied it to a 
competition assay in combination with FK506 and rapamycin, as sequestration of free 
FKBP will prevent the formation of active FKBP12-FK506 or FKBP-rapamycin 
complexes and thus antagonizing the activity of both drugs (Rao et al., 1997, Abraham et 
al., 1996).  
 The effect of FK506 on calcineurin was determined using as a readout the 
phosphorylation state of NFATc2. Thus, FK506 blocked the dephosphorylation of 
NFATc2 in response to stimulation with PMA and ionomycin (Fig. 3.2A). The 
presence of 10 µM of FKVP reversed the inhibitory effect of FK506 on NFATc2 
dephosphorylation (Figure 1.2), suggesting mutual antagonism between FKVP and 
FK506. Similarly, we examined the effect of rapamycin on mTOR activity as judged 
by the phosphorylation state of its substrate p70s6k. Once again, high concentration 
of FKVP reversed the inhibition of rapamycin on p70s6k phosphorylation (Fig. 
3.2B). Together, these results clearly showed that FKVP is capable of antagonizing 
the activities of both FK506 and rapamycin through competitive binding to 






Figure 3.2: FKVP competes both FK506 and Rapamycin for FKBP12 binding Both 
FK506 and rapamycin require FKBP12 for activity. (A) FKVP blocks FK506 
inhibition of calcineurin-mediated NFAT dephosphorylation (lower band), (B) as well as 
inhibition of mTOR-mediated S6 phosphorylation by rapamycin. 
 
FKVP in combination with AMD3100 accelerated wound healing. 
We have previously reported the synergistic activity of AMD3100 and FKVP 
(AV) in accelerating wound healing after full-thickness skin excision. To further confirm 
this finding, we performed a wound healing experiment in a rat model of type 2 diabetes. 
Four full-thickness wounds were generated by 8-mm diameter circular excisions on the 
shaved back of a diabetic GK rat and each wound site was photographed digitally at the 
indicated time intervals (Fig. 3.3A). Re-epithelialization of entire wound areas was used 
as a defining parameter of complete healing, and the complete healing time of four 
wounds in each animal were calculated in days (Fig. 3.3B). Wounded rats were divided 
randomly into three experimental groups and received subcutaneous injections of saline, 
AF (AMD3100 (1.0 mg/kg) plus FK506 (0.1 mg/kg)) or AV (AMD3100 plus FKVP (0.1 
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mg/kg)) immediately after wounding and every other day until complete healing. While 
the saline control group showed an average complete healing time of 26 days, the animals 
treated with AF exhibited significantly faster healing as wounds reached complete re- 
epithelialization at day 21, which is consistent with our report in non-diabetic rodent 
models of surgical excisional wounds (Lin et al., 2014). Importantly, ten rats receiving 
AV therapy displayed an AF-equivalent effect of significantly reduced time for complete 
healing from 26 to 20 days (Fig. 3.3C). These results strongly suggest that inhibition of 
calcineurin is not involved in the synergistic activity of AMD3100 and FK506 in 
accelerating wound healing.  
 
Figure 3.3: Accelerated wound healing in diabetic GK rats treated with combination 
of AMD3100 and FK506 or FKVP. (A) The wound model: four circular excisional 
wounds (8-mm in diameter) were created on the dorsal of GK rats.  (B) Representative 
photographs of wounds in GK rats for each treatment group (AF=AMD3100+FK506, 
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AV=AMD3100+FKVP), at days 0, 6, 12, 18 and 24. (C) Quantitative analysis of 
complete healing time in GK rats. All data represented by mean ± SEM.   
 
FKVP activates ID-1 reporter and SMAD1/5 phosphorylation through BMP type 1 
receptor  
Having ruled out calcineurin as a relevant mediator of the WH acceleration activity 
of FK506, we turned to FKBP12 and the BMP signaling pathway it is reported to 
regulate (Figure 1.3). We began by determining whether FK506 and FKVP are both 
capable of activating the BMP signaling pathway by employing a BMP-response-
element (BRE) pathway reporter (luciferase under the control of the ID1 gene 
promoter) (Figure 2.7) (Spiekerkoetter et al., 2013) in Jurkat [E6.1] T cells. The 
Jurkat line was found to express working components of BMP signaling (BMPRs, 
SMAD1/5) in addition to high levels of FKBP12 and CXCR4, making it an excellent 
model system. To confirm reporter selectivity, rBMP-4 and rTGF-β1 were used as 
positive and negative controls, respectively. Treatment with both FKVP and FK506 
caused dose-dependent activation of the reporter, and the increases in luciferase 
activity were completely blocked by the selective BMP1R inhibitor LDN-193189 
(LDN) (Fig. 3.4). In contrast to FK506 and FKVP, cyclosporine A (CsA) did not 
activate the reporter (Fig. 3.4), consistent with the notion that calcineurin is not 




Figure 3.4: FKVP activates ID-1 reporter and pSMAD1/5 phosphorylation through 
BMP type 1 receptor activation. (A) BMP-response-element (BRE) reporter activity in 
Jurkat cells after treatment with increasing amounts of FK506 and FKVP. This activity is 
strongly inhibited by the addition of 100 nM LDN-193182. TGF-β1 serves as negative 
control, while BMP4 shows strong induction of luciferase expression after 18 hours. 
Relative luciferase activities were determined upon normalization to DMSO control 




To study downstream BMPR1 signaling events, we determined the effects of 
FK506 and FKVP on the phosphorylation of SMAD1/5. Both compounds induced 
SMAD1/5 phosphorylation in a dose-dependent manner (Fig. 3.5A), an effect abolished 




Figure 3.5: Western blotting for FKVP-induced SMAD1/5 phosphorylation in 
Jurkat cells. (A) Dose-dependent induction of SMAD1/5 phosphorylation by 2 hour 
FKVP treatment in Jurkat cells. (B) BMPR1-selective inhibitor LDN-193189 inhibits 








In contrast, there were no increases in phosphorylated SMAD2/3 under the same 
conditions (Fig. 3.6), suggesting that while FKBP12 may bind TGF-β receptors (Chen et 
al., 1997), its dissociation is insufficient to activate receptor kinase activity in the absence 
of TGF-β. This result is in agreement with previous studies showing that FK506 and non-
immunosuppressive analogs are incapable of activating TGF-β pathway reporters without 
the addition of exogenous ligand (Spiekerkoetter et al., 2013; Wang et al., 1996). 
 
Figure 3.6: Western blotting for FKVP-induced SMAD2/3 phosphorylation in 
Jurkat cells. After 2 hours, FKVP does not induce SMAD2/3 phosphorylation in Jurkat 
cells compared to TGF-β1 (positive control). 
 
 In the BRE-luciferase reporter, AMD3100 was found to have no significant effect 
on ID-1 promoter stimulation alone or in combination with FKVP (Fig. 3.7). This 
suggests that the synergistic activity of these drugs does not converge at BMP signaling. 
A previous report has suggests that BMP-9 treatment enhances CXCR4 mRNA 
47 
 
expression in endothelial cells (Young et al, 2012), but it remains to be seen if small-
molecule BMP activation can mimic this effect. 
 
Figure 3.7: AMD-3100 does not affect BMP signaling alone, or in combination with 
FKVP. FKVP and AMD3100 single and combination treatments in Jurkat BMP 
activation luciferase assay (n=3). Relative luciferase activities were determined upon 
normalization to DMSO control values. Error bars represent standard deviation from 
mean. 
 
The extracellular space contains several extracellular BMP inhibitors that are 
critical for embryogenesis and stem cell differentiation. These ubiquitous proteins bind to 
BMPs, preventing activation of BMPR and downstream signaling. This environment may 
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complicate the use of recombinant BMP protein for clinical uses. Conversely, we found 
that the extracellular BMP-inhibitor protein, noggin, was not effective at reducing 
FK506- or FKVP-mediated induction of the BMP reporter (Fig. 3.8). These observations 
suggest that endogenous BMP is not required for signaling activation by FK506 or 
FKVP, and that these compounds could activate BMP in tissues with under-expression of 
BMP protein, or overexpression of extracellular inhibitors like noggin. 
 
Figure 3.8: FKVP Activates BMP Signaling in the presence of the BMP inhibitor, 
Noggin. BMP-4, FKVP, FK506, and Noggin combination treatments in Jurkat BMP 
activation luciferase assay (n=3). Relative luciferase activities were determined upon 




 In addition, FKVP boosted the sensitivity of cells to BMP-4 stimulation in an 
additive fashion, suggesting that inhibition of FKBP12 binding promotes receptor 
activation by endogenous ligand (Fig. 3.9).  While this is also observed in the case of 
TGF-β signaling (Wang et al, 1997), only BMP receptors have been found to be activated 
by FKBP12 inhibition in the absence of exogenous ligand (Figure 3.8). The reasoning 
for this may stem from the subtle differences in activation of the two receptor types 
(Mueller et al., 2015).  
   
Figure 3.9: FKVP increases sensitivity of cells to BMP-4 stimulation. BMP-4, FKVP, 
and combination treatments in Jurkat BMP activation luciferase assay (n=3). Relative 
luciferase activities were determined upon normalization to DMSO control values. Error 





In addition to Jurkat, SMAD1/5 phosphorylation was significantly increased in 
HUVEC cells after FKVP treatment (Fig. 3.10), providing evidence that more than one 
cell type is sensitive to BMP activation by FKVP. A transient increase in erk (Fig. 3.10b) 
phosphorylation was found to occur as SMAD1/5 phosphorylation reached 50 percent. 
    
 
Figure 3.10: FKVP activates SMAD1/5 and ERK1/2 phosphorylation in HUVEC. 
(A) Western blot of SMAD1/5 phosphorylation after 2 hour treatment with BMP-4, 
FKVP, or LDN combination treatments in HUVEC cells. (B) Time-course western blot 




 A dominant downstream target of BMP pathway activation  is ID protein 
expression. This class of proteins uses a pseudo-domain to bind and inhibit transcription 
factors involved in several cellular processes. We found that FKVP strongly activated 
ID1 expression in HUVEC cells as early as 1 hour after treatment. This increase 
coincides with the maximum state of SMAD1/5 phosphorylation (1 hour) after compound 
treatment (Figure 3.10b). 
 
 
Figure 3.11: FKVP activates ID-1 expression in HUVEC. Time-course western blot of 
HUVEC cells treated with 200 nM FKVP and blotted for ID-1 expression. FKBP12 and 
HSP90 serve as loading controls. 
 
 Beyond canonical signaling, BMP receptor activation has been shown to crosstalk 
with other signaling pathways using BMP type 2 receptors.  FKVP treatment was found 
to mimic these effects in a time-dependent manner. Specifically, a potent but transient 
increase in akt phosphorylation occurs just as SMAD1/5 phosphorylation begins to 
increase (Fig. 3.12). Furthermore, a modest increase in JNK phosphorylation was seen 
during the timeframe of peak SMAD1/5 phosphorylation (Fig. 3.13). This presents a 
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complex model of BMP activation by FKVP, as previous reports state that only BMPR1 
is inhibited by FKBP12 (Wang et al, 1997).  If BMPR2 is indeed activated by FKVP, it is 
most likely a result of association with an uninhibited BMPR1. 
 
 
Figure 3.12: FKVP activates transient Akt phosphorylation in HUVEC. Time-course 
western blot of HUVEC cells treated with 200nM FKVP and blotted for phospho-Akt. 
Total Akt and HSP90 serve as loading controls. 
 
 
Figure 3.13: FKVP activates JNK phosphorylation in HUVEC. Time-course western 
blot of HUVEC cells treated with 200nM FKVP and blotted for phospho-JNK. Total JNK 
and HSP90 serve as loading controls. 
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 To further challenge the ability of FKVP to activate TGF-B signaling, we probed 
for time dependent SMAD2/3 phosphorylation in HUVEC cells after compound 
treatment. Western blotting revealed a modest increase in SMAD2/3 phosphorylation that 
persisted through 26 hours, though this effect is not as prominent as seen in SMAD1/5 
phosphorylation (Fig. 3.10b).  Conversely, it can be suggested that DMSO treated cells 
also showed a time dependent increase. This may be a result of autocrine TGF-β 
signaling that occurs as cells divide and become more numerous within culture. HUVEC 
cells most likely produce more TGF-β protein than Jurkat cells, allowing FKBP12 
antagonism to promote kinase activity in the presence of ligand. 
 
 
Figure 3.14: FKVP weakly increases SMAD2/3 phosphorylation in HUVEC. Time-
course western blot of HUVEC cells treated with 200nM FKVP and blotted for phospho-
SMAD2/3. Total SMAD2/3 and HSP90 serve as loading controls. 
 
 Together, these results indicated that both FK506 and FKVP are capable of 
activating BMPR1 kinase signaling, raising the possibility that this activation plays a key 
role in the healing acceleration activity of FK506 in the AF combination therapy.  
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FKBP12 alone is required for FKVP-induced SMAD1/5 phosphorylation. 
FKBP12 is a member of the FKBP superfamily of proteins. In previous work, 
FKBP12 has been shown to be associated with the BMPR1 activin-like kinase 2 (ALK2). 
However, attempts to knock down several FKBPs failed to reveal a specific effect on 
BMPR1 signaling (Spiekerkoetter et al., 2013), likely due to the relative stability and 
high abundance of FKBPs. To address this problem, we generated CRISPR-Cas9 
knockouts of three cytosolic FKBPs, FKBP12, FKBP51, and FKBP52 (Fig. 3.15).  
 
Figure 3.15: Representative plot of Jurkat FKBP-knockout cell sorting. Transfected 
Jurkat cells were single-cell sorted by m-cherry fluorescence (650nm laser) and PI 
staining into 96-well plates. Left panel indicates negative control cells, while right panel 
shows gating of m-cherry positive cells. 
55 
 
All three FKBP proteins have been reported to bind FK506 (Kozany et al., 2009). 
In the BRE-luciferase reporter assay, it was found that only FKBP12 knockout cells lost 
sensitivity to FK506 and FKVP (Fig. 3.16). While BMP activation looks to be reduced 
by FKBP12 knockout, the total value was actually higher. This is because FKBP12 
knockout produces induces a BMP activated cell type with increased basal (DMSO) 
reporter activity. 
 
Figure 3.16: FKBP12 alone is required for FK506 and FKVP-induced SMAD1/5 
phosphorylation. Activation of BMP pathway reporter by FKVP and FK506 in different 
FKBP isoform knockout cells and inhibition of the reporter gene activation by LDN (n = 
3). Relative luciferase activities were determined upon normalization to DMSO control 
values. Error bars represent standard deviation from mean. 
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In agreement with reporter assays, it can be seen that FKBP12KO cells showed 
constitutively elevated levels of SMAD1/5 phosphorylation and resistance to further 
activation by FKVP (Fig. 3.17).  
 
 
Figure 3.17: FKBP12 knockout cells show enhanced basal SMAD1/5 
phosphorylation, and are insensitive to FKVP.  Induction of SMAD1/5 








To further validate FKBP12, we designed a fusion protein that could be used for 
further pulldown experiments. This protein was designed to include a c-terminal SNAP 
tag, known to covalently bind specialized probes. Using RaptorX software, we are able to 
model the fusion construct as evidence that the FK506 binding pocket was unobstructed. 
Furthermore, reconstitution of FKBP12 knockout cells with the fusion construct restored 
FK506/FKVP sensitivity in KO cells to that of the original parental line (Fig. 3.18). 
These results show that the designed FKBP12-SNAP protein retains the ability to bind 
either BMPR or FKVP/FK506. 
 
 
Figure 3.18: FKBP12-SNAP fusion construct restores FK506 and FKVP sensitivity 
in FKBP12 knockout cells. (A) BMP reporter assay in FKBP12KO cells show that 
expression of a novel FKBP12-SNAP fusion protein restores activation potential of 




We were able to use the aforementioned FKBP12-SNAP fusion protein to pull 
down calcineurin and mTOR in the presence of FK506 and rapamycin, respectively (Fig. 
3.19). This further validates the use of FKBP12-SNAP for pulldown of BMP receptors, 
as it can be seen that all molecular targets of FKBP12 can be precipitated when the 
adaptor molecule is added. Moreover, the lack of staining in samples treated with FKVP 
supports the claim that FKVP does not cause FKBP12 to associate with calcineurin. 
 
Figure 3.19: FKBP12-SNAP interacts with both mTOR and calcineurin. SNAP-tag 
pull-down and western blot showing that FKBP12-SNAP efficiently associates with both 
calcineurin and mTOR in the presence of FK506 and rapamycin, respectively. As a 
negative control, FKVP does not induce calcineurin association.  BMP protein treatments 
were not probed for this experiment. 
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Continuing from our validation of FKBP12-SNAP in pulldown experiments, we 
then applied the same construct to pull down V5- or HA-tagged ALK (BMPR1) receptors 
from transfected HEK293T cells. From western blotting, we observed that SNAP-
FKBP12 and ALK receptors did indeed interact with each other and the association was 
sensitive to competition by FKVP (Fig. 3.20 - Fig 3.26).  This effect was most prominent 
in ALKs 1, 2, 3, and 5. The first three of these receptors (ALK 1,2,3) activate BMP 
signaling, while ALK 5 is the primary TGF-β type 1 receptor. These results suggest that 
FKVP and other FKBP12 antagonists act as pan BMP activators, where the receptor and 
level of activation are dependent on receptor expression. 
 
 
Figure 3.20: Pulldown of ALK1 receptor by FKBP12 is competed by FKVP 
treatment. V5-tagged ALK1 receptor and FKBP12-SNAP were co-expressed in 
FKBP12KO Hek293T cells, and SNAP-functionalized beads were used to precipitate 




Figure 3.21: Pulldown of ALK2 receptor by FKBP12 is competed by FKVP 
treatment. HA-tagged ALK2 receptor and FKBP12-SNAP were co-expressed in 
FKBP12KO Hek293T cells, and SNAP-functionalized beads were used to precipitate 










Figure 3.22: Pulldown of ALK3 receptor by FKBP12 is competed by FKVP 
treatment. HA-tagged ALK3 receptor and FKBP12-SNAP were co-expressed in 
FKBP12KO Hek293T cells, and SNAP-functionalized beads were used to precipitate 





Figure 3.23: Pulldown of ALK4 receptor by FKBP12 is competed by FKVP 
treatment. HA-tagged ALK4 receptor and FKBP12-SNAP were co-expressed in 
FKBP12KO Hek293T cells, and SNAP-functionalized beads were used to precipitate 






Figure 3.24: Pulldown of ALK5 receptor by FKBP12 is competed by FKVP 
treatment. HA-tagged ALK5 receptor and FKBP12-SNAP were co-expressed in 
FKBP12KO Hek293T cells, and SNAP-functionalized beads were used to precipitate 





Figure 3.25: Pulldown of ALK6 receptor by FKBP12 is competed by FKVP 
treatment. HA-tagged ALK6 receptor and FKBP12-SNAP were co-expressed in 
FKBP12KO Hek293T cells, and SNAP-functionalized beads were used to precipitate 





Figure 3.26: Pulldown of ALK7 receptor by FKBP12 is competed by FKVP 
treatment. HA-tagged ALK7 receptor and FKBP12-SNAP were co-expressed in 
FKBP12KO Hek293T cells, and SNAP-functionalized beads were used to precipitate 









BMP signaling is required for the effect of AF combination in accelerating wound 
healing 
To determine if BMP activation by FK506 is responsible for accelerated wound 
healing, a selective BMPR1 kinase inhibitor, LDN-193189 (2mg/kg/day, i.p.) was 
administered to wounded GK rats treated with saline or AF combination. LDN has been 
shown effective in vivo (Cuny et al., 2008; Sun et al., 2013), and alone showed no effect 
on wound healing. Interestingly, LDN abolished the beneficial effect of AF combination 




Figure 3.27: Blockade of BMP signaling abrogates the beneficial effect of AF 
combination therapy in wound healing. (A) Representative photographs of wounds in 
GK rats treated with saline, LDN, AF or AF plus LDN showing difference between AF 
and AF plus LDN beginning at day 12. (B) Quantitative analysis of complete healing 
time in GK rats. All data represented by mean ± SEM. 
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We have reported that FK506 plays a key role in recruitment of AMD3100 
mobilized CD133 stem cells into wound sites (Lin et al., 2014) or injured organs 
(Okabayashi et al., 2011; Hu et al., 2016; Cameron et al., 2016; Zhai et al., 2018). To 
further confirm if blocking BMP signaling inhibits the recruitment of stem cells, we 
performed immunohistochemistry staining for CD133 in wound tissue sections recovered 
from animals at day 7 after surgery. A few CD133+ cells were identified in wound tissue 
sections from animals treated with saline (Fig. 3.28). The number of CD133+ cells was 
significantly increased in newly formed granulation tissues of the wounds in animals 
receiving AF combination therapy. Strikingly, administration of BMP inhibitor LDN 
dramatically reduced the number of CD133+ cells in the wounds in animals with AF 
combination treatment.  Taken together, these results suggest that the recruitment of more 
CD133+ stem cells into the wound sites by AF combination treatment depends on BMP 
activation by FK506, and that blockade of BMP signaling with LDN eliminates the 







Figure 3.28: Blockade of BMP signaling prevents CD133 recruitment induced by AF 
combination therapy.  Representative immunohistochemical staining for the stem cell 
marker CD133 in granulation tissues of GK rats at day 7. The rats receiving AF treatment 
had significantly higher number of CD133 cells (brown) in granulation tissues compared 
to the saline control group, while LDN treatment dramatically reduced the number of 











To detect in vivo SMAD1/5 phosphorylation, we employed a PE-conjugated 
pSMAD1/5 antibody to measure BMP activation by flow cytometry. Preliminary in vitro 
testing in Jurkat cells showed 2 hour FKVP or BMP-4 treatment resulted in increased 
staining, while DMSO results resembled the unstained control (Fig. 3.29). 
 
 
Figure 3.29: Flow cytometry testing of pSMAD1/5-PE antibody in Jurkat cells. 
Twenty thousand events were collected for each group after 2 hour treatment. Both 





To measure in vivo SMAD1/5 phosphorylation in stem cells, we co-stained 
PBMCs from treated GK rats with antibodies for both pSMAD1/5 and the surface marker 
CD133. While the results were insignificant due to small sample size, there is a trend of 
increased pSMAD+CD133+ cells after AF treatment that is mildly reduced by LDN co-
treatment (Fig. 3.30). 
 
Figure 3.30: BMP inhibitor LDN may reduce AF-induced SMAD1/5 
phosphorylation in circulating CD133+ cells of GK rats. GK rats were treated with 
ether saline, AF therapy, or AF + LDN for 3 hours before PBMC isolation and staining 
for CD133 and pSMAD1/5. AF therapy appears to increase SMAD1/5 phosphorylation in 
CD133+ cells, and this increase may be reduced by LDN treatment. Final results were 
insignificant but could be improved by proper timing of treatment administration and 
increased sample size. 
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We questioned whether or not SMAD1/5 phosphorylation could influence 
endothelial progenitor cell mobilization, aiding in wound healing through increased 
neovascularization. PBMCs from treated GK rats were stained for both CD133 and 
CD31, an endothelial cell marker. AF treatment significantly enhanced endothelial 
progenitor mobilization, an effect rendered insignificant by co-administration of the BMP 
inhibitor LDN (Fig. 3.31). 
 
 
Figure 3.31: BMP inhibitor LDN reduces circulating CD133+ CD31+ cells in GK 
rats after AF treatment. GK rats were treated with ether saline, AF therapy, or AF + 
LDN for 3 hours before PBMC isolation and staining for extracellular markers. LDN 
affectively reduced the number of cells mobilized by AF therapy to the point of 




Reagents and Materials 
Reactions were monitored by mass spectrometry provided by Agilent 6120 Quadrupole 
LC/MS. PLC Silica gel 60 F254, 1mm supplied by EMD Millipore using UV light as 
visualizing agent. 
1H-NMR was recorded on Bruker Avance III 500 MHz NMR spectrometer. TMS was 
used as internal standard for 1H-NMR (0 ppm). High-resolution mass spectra (HRMS) 
were recorded on Waters Synapt G2-Si mass spectrometer using ESI (electrospray 
ionization). FK-506 (Tacrolimus) was purchased from Biotang Inc. Zhan-1b catalyst, 
palladium acetate and tris(o-tolyl)phosphine were purchased from Aldrich.  
Chemicals: Research-grade FK506 (>98%) was purchased from APExBIO. LDN-193189 
hydrochloride, 4-vinylpyridine, and solvents were purchased form MilliporeSigma. Zhan-
1b Ruthenium catalyst (CAS: 918870-76-5) was purchased from STREM Chemicals. 
 
Cell Culture and Transfections 
Jurkat (E6.1, ATCC) cells were cultured in RPMI with 10% FBS and 1.5% PennStrep. 
Jurkat cells (1 x 106 ) were transfected with 10 μg of BRE-Luciferase (kindly provided by 
Martine Roussel & Peter ten Dijke) or NFAT-Luciferase cDNA (Promega) by 
electroporation (BioRad, square-wave, 250V, 950μF) in 400 μL serum/antibiotic free 
RPMI with 0.5% DMSO. Thirty minutes after transfection, cells were transferred to 
complete RPMI and rested overnight. Before plating, cells were re-suspended in fresh 
73 
 
media and diluted to 0.5x106 cells/mL. HEK293T cells were cultured in DMEM with 
10% FBS, 1% PennStrep, and 500 µg/mL G418 (Corning). Cells were transfected using 
SuperFect reagent and supplied transfection protocols. HUVEC cells were cultured in 
Lonza Endothelial Cell Growth Medium (EGM-2) and used between passages 3 and 7. 
All cells were cultured at 37 °C with 5% CO2. 
 
Cell Viability Assays 
Jurkat or HUVEC cells were plated at 1000 cells/well in 180 μL growth media before 
addition of 20 μL of 10X drug/protein stock. After incubation for 72 h, 22 µL of a 
resazurin sodium salt solution (0.1 mg/mL stock in water) was added to each well and 
allowed to incubate at 37°C. The metabolic conversion of resazurin dye was monitored 
by absorbance at 570 nm after 6 h. After background subtraction (media only + dye), 
absorbance values were left as arbitrary absorbance units or normalized to those obtained 
from cells treated with DMSO. 
 
Western Blot 
Jurkat T cells were collected by centrifugation (300g, 5 min), washed with PBS, and 
lysed in RIPA buffer containing protease and phosphatase inhibitors (Cell Signaling) 
with sonication. Lysates were normalized using DC assay (BioRad) and run on SDS-
PAGE gels. Proteins were transferred to nitrocellulose membranes overnight at 100mA. 
After blocking with 5% milk in TBS-T for 20 min, membranes were incubated overnight 
at 4°C with primary antibodies (Table 3.1). After washing three times with TBS-T, 
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membranes were incubated with secondary antibody (Table 3.1) for 1 hour. After 3 
additional washes, blots were visualized using SynGene, either using ECL substrate 
(Thermo) or laser excitation and filter (647nm). 
 
Table 3.1: Manufacturers’ information and recommended concentrations of 
antibodies for western blotting and IHC. 
Target Conjugate Recommended Concentration Manufacturer Catalog # Antibody Usage 
p-SMAD1/5 None 1:750 Cell Signaling 41D10 WB Primary 
SMAD1 None 1:500 Cell Signaling 9473S WB Primary 
p-SMAD2/3 None 1:400 Cell Signaling 8828S WB Primary 
NFATc2 None 1:100 Santa Cruz SC-7296 WB Primary 
p-S6 None 1:1000 Santa Cruz SC-293144 WB Primary 
S6 None 1:1000 Cell Signaling 2217 WB Primary 
ID1 HRP 1:100 or 1:500 w/secondary Santa Cruz 
SC-133104-
HRP WB Primary 
FKBP12 None 1:750 Abcam 92459 WB Primary 
FKBP51 None 1:750 Abcam Ab126715 WB Primary 
FKBP52 None 1:750 Santa Cruz SC-1803 WB Primary 
mTOR None 1:1000 Cell Signaling 2983S WB Primary 
Pan Calcineurin None 1:1000 Cell Signaling 2614S WB Primary 
HA-Tag None 1:1000 Cell Signaling 3724S WB Primary 
V5-Tag None 1:1000 Thermo 46-0705 WB Primary 
HSP90α/β None 1:1000 Santa Cruz SC-13119 Loading Control (WB Primary) 
GAPDH None 1:2000 Santa Cruz SC-20357 Loading Control (WB Primary) 
HSP90α/β None 1:1000 Santa Cruz SC-7947 Loading Control (WB Primary) 
Rabbit 2°Ab HRP 1:10000 Cell Signaling 7074S WB Secondary 
Rabbit 2°Ab Alexa 647 1:1000 Thermo A-31573 WB Secondary 
Mouse 2°Ab HRP 1:8000 GE Healthcare NA931V WB Secondary 
Goat 2°Ab HRP 1:10000 Santa Cruz SC-2354 WB Secondary 
CD133 None 1:300 Abcam ab19898 IHC Primary 




FKBP12-SNAP was cloned using pSNAPf vector (New England Bio) and PCR-amplified 
FKBP12 (a gift from Tobias Meyer, Addgene plasmid # 20175) with added EcoRI and 
BsrGI restriction sites. Gel-purified plasmids were ligated using T4 DNA ligase 
(Thermo), transformed into DH5α, and plated on LB-agar plus ampicillin for single 
colony selection, sequencing, and plasmid purification. 
FKBP12-SNAP Full Sequence: Deduced from CMV-forward primer sequencing aligned 
with sequences provided by NEB (6166 bp) 
1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTGCACTCT CAGTACAATC TGCTCTGATG 
61 CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG 
121 CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC 
181 TTAGGGTTAG GCGTTTTGCG CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT 
241 GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA 
301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 
361 CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC 
421 ATTGACGTCA ATGGGTGGAG TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT 
481 ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT 
541 ATGCCCAGTA CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA 
601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 
661 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC 
721 AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG 
781 GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA 
841 CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTTGGTACC 
901 GAGCTCGGAT CGTCGCTAGC GATATCGGCG CGCCAGCATT TAAATCTGTA CAATGGGAGT 
961 GCAGGTGGAA ACCATCTCCC CAGGAGACGG GCGCACCTTC CCCAAGCGCG GCCAGACCTG 
1021 CGTGGTGCAC TACACCGGGA TGCTTGAAGA TGGAAAGAAA TTTGATTCCT CCCGGGACAG 
1081 AAACAAGCCC TTTAAGTTTA TGCTAGGCAA GCAGGAGGTG ATCCGAGGCT GGGAAGAAGG 
1141 GGTTGCCCAG ATGAGTGTGG GTCAGAGAGC CAAACTGACT ATATCTCCAG ATTATGCCTA 
1201 TGGTGCCACT GGGCACCCAG GCATCATCCC ACCACATGCC ACTCTCGTCT TCGATGTGGA 
1261 GCTTCTAAAA CTGGAAGAAT TCACCATGGA CAAAGACTGC GAAATGAAGC GCACCACCCT 
1321 GGATAGCCCT CTGGGCAAGC TGGAACTGTC TGGGTGCGAA CAGGGCCTGC ACCGTATCAT 
1381 CTTCCTGGGC AAAGGAACAT CTGCCGCCGA CGCCGTGGAA GTGCCTGCCC CAGCCGCCGT 
1441 GCTGGGCGGA CCAGAGCCAC TGATGCAGGC CACCGCCTGG CTCAACGCCT ACTTTCACCA 
1501 GCCTGAGGCC ATCGAGGAGT TCCCTGTGCC AGCCCTGCAC CACCCAGTGT TCCAGCAGGA 
1561 GAGCTTTACC CGCCAGGTGC TGTGGAAACT GCTGAAAGTG GTGAAGTTCG GAGAGGTCAT 
1621 CAGCTACAGC CACCTGGCCG CCCTGGCCGG CAATCCCGCC GCCACCGCCG CCGTGAAAAC 
1681 CGCCCTGAGC GGAAATCCCG TGCCCATTCT GATCCCCTGC CACCGGGTGG TGCAGGGCGA 
1741 CCTGGACGTG GGGGGCTACG AGGGCGGGCT CGCCGTGAAA GAGTGGCTGC TGGCCCACGA 
1801 GGGCCACAGA CTGGGCAAGC CTGGGCTGGG TCCTGCAGGC GGATCCGCGT TTAAACTCGA 
1861 GGTTAATTAA TGAGCGGCCG CATAGATAAC TGATCCAGTG TGCTGGAATT AATTCGCTGT 
1921 CTGCGAGGGC CAGCTGTTGG GGTGAGTACT CCCTCTCAAA AGCGGGCATG ACTTCTGCGC 
1981 TAAGATTGTC AGTTTCCAAA AACGAGGAGG ATTTGATATT CACCTGGCCC GCGGTGATGC 
2041 CTTTGAGGGT GGCCGCGTCC ATCTGGTCAG AAAAGACAAT CTTTTTGTTG TCAAGCTTGA 
2101 GGTGTGGCAG GCTTGAGATC TGGCCATACA CTTGAGTGAC AATGACATCC ACTTTGCCTT 
2161 TCTCTCCACA GGTGTCCACT CCCAGGTCCA ACTGCAGGTC GAGCATGCAT CTAGGGCGGC 
2221 CAATTCCGCC CCTCTCCCCC CCCCCCTTTT CCCTCCCCCC CCCCTAACGT TACTGGCCGA 
2281 AGCCGCTTGG AATAAGGCCG GTGTGCGTTT GTCTATATGT TATTTTCCAC CATATTGCCG 
2341 TCTTTTGGCA ATGTGAGGGC CCGGAAACCT GGCCCTGTCT TCTTGACGAG CATTCCTAGG 
2401 GGTCTTTCCC CTCTCGCCAA AGGAATGCAA GGTCTGTTGA ATGTCGTGAA GGAAGCAGTT 
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2461 CCTCTGGAAG CTTCTTGAAG ACAAACAACG TCTGTAGCGA CCCTTTGCAG GCAGCGGAAC 
2521 CCCCCACCTG GCGACAGGTG CCTCTGCGGC CAAAAGCCAC GTGTATAAGA TACACCTGCA 
2581 AAGGCGGCAC AACCCCAGTG CCACGTTGTG AGTTGGATAG TTGTGGAAAG AGTCAAATGG 
2641 CTCTCCTCAA GCGTATTCAA CAAGGGGCTG AAGGATGCCC AGAAGGTACC CCATTGTATG 
2701 GGATCTGATC TGGGGCCTCG GTGCACATGC TTTACATGTG TTTAGTCGAG GTTAAAAAAA 
2761 CGTCTAGGCC CCCCGAACCA CGGGGACGTG GTTTTCCTTT GAAAAACACG ATGATAAGCT 
2821 TGCCACAACC CGGGATAATT CCTGCAGCCA ATATGGGATC GGCCATTGAA CAAGATGGAT 
2881 TGCACGCAGG TTCTCCGGCC GCTTGGGTGG AGAGGCTATT CGGCTATGAC TGGGCACAAC 
2941 AGACAATCGG CTGCTCTGAT GCCGCCGTGT TCCGGCTGTC AGCGCAGGGG CGCCCGGTTC 
3001 TTTTTGTCAA GACCGACCTG TCCGGTGCCC TGAATGAACT GCAGGACGAG GCAGCGCGGC 
3061 TATCGTGGCT GGCCACGACG GGCGTTCCTT GCGCAGCTGT GCTCGACGTT GTCACTGAAG 
3121 CGGGAAGGGA CTGGCTGCTA TTGGGCGAAG TGCCGGGGCA GGATCTCCTG TCATCTCACC 
3181 TTGCTCCTGC CGAGAAAGTA TCCATCATGG CTGATGCAAT GCGGCGGCTG CATACGCTTG 
3241 ATCCGGCTAC CTGCCCATTC GACCACCAAG CGAAACATCG CATCGAGCGA GCACGTACTC 
3301 GGATGGAAGC CGGTCTTGTC GATCAGGATG ATCTGGACGA AGAGCATCAG GGGCTCGCGC 
3361 CAGCCGAACT GTTCGCCAGG CTCAAGGCGC GCATGCCCGA CGGCGATGAT CTCGTCGTGA 
3421 CCCATGGCGA TGCCTGCTTG CCGAATATCA TGGTGGAAAA TGGCCGCTTT TCTGGATTCA 
3481 TCGACTGTGG CCGGCTGGGT GTGGCGGACC GCTATCAGGA CATAGCGTTG GCTACCCGTG 
3541 ATATTGCTGA AGAGCTTGGC GGCGAATGGG CTGACCGCTT CCTCGTGCTT TACGGTATCG 
3601 CCGCTCCCGA TTCGCAGCGC ATCGCCTTCT ATCGCCTTCT TGACGAGTTC TTCTGAGGGG 
3661 ATCAATTCTC TAGATAACTG ATCATAATCA GCCATACCAC ATTTGTAGAG GTTTTACTTG 
3721 CTTTAAAAAA CCTCCCACAC CTCCCCCTGA ACCTGAAACA TAAAATGAAT GCAATTGTTG 
3781 TTGTTAACTT GTTTATTGCA GCTTATAATG GTTACAAATA AAGCAATAGC ATCACAAATT 
3841 TCACAAATAA AGCATTTTTT TCACTGCATT CTAGTTGTGG TTTGTCCAAA CTCATCAATG 
3901 TATCTTAACG CGTCGAGTGC ATTCTAGTTG TGGTTTGTCC AAACTCATCA ATGTATCTTA 
3961 TCATGTCTGT ATACCGTCGA CCTCTAGCTA GAGCTTGGCG TAATCATGGT CATAGCTGTT 
4021 TCCTGTGTGA AATTGTTATC CGCTCACAAT TCCACACAAC ATACGAGCCG GAAGCATAAA 
4081 GTGTAAAGCC TGGGGTGCCT AATGAGTGAG CTAACTCACA TTAATTGCGT TGCGCTCACT 
4141 GCCCGCTTTC CAGTCGGGAA ACCTGTCGTG CCAGCTGCAT TAATGAATCG GCCAACGCGC 
4201 GGGGAGAGGC GGTTTGCGTA TTGGGCGCTC TTCCGCTTCC TCGCTCACTG ACTCGCTGCG 
4261 CTCGGTCGTT CGGCTGCGGC GAGCGGTATC AGCTCACTCA AAGGCGGTAA TACGGTTATC 
4321 CACAGAATCA GGGGATAACG CAGGAAAGAA CATGTGAGCA AAAGGCCAGC AAAAGGCCAG 
4381 GAACCGTAAA AAGGCCGCGT TGCTGGCGTT TTTCCATAGG CTCCGCCCCC CTGACGAGCA 
4441 TCACAAAAAT CGACGCTCAA GTCAGAGGTG GCGAAACCCG ACAGGACTAT AAAGATACCA 
4501 GGCGTTTCCC CCTGGAAGCT CCCTCGTGCG CTCTCCTGTT CCGACCCTGC CGCTTACCGG 
4561 ATACCTGTCC GCCTTTCTCC CTTCGGGAAG CGTGGCGCTT TCTCATAGCT CACGCTGTAG 
4621 GTATCTCAGT TCGGTGTAGG TCGTTCGCTC CAAGCTGGGC TGTGTGCACG AACCCCCCGT 
4681 TCAGCCCGAC CGCTGCGCCT TATCCGGTAA CTATCGTCTT GAGTCCAACC CGGTAAGACA 
4741 CGACTTATCG CCACTGGCAG CAGCCACTGG TAACAGGATT AGCAGAGCGA GGTATGTAGG 
4801 CGGTGCTACA GAGTTCTTGA AGTGGTGGCC TAACTACGGC TACACTAGAA GAACAGTATT 
4861 TGGTATCTGC GCTCTGCTGA AGCCAGTTAC CTTCGGAAAA AGAGTTGGTA GCTCTTGATC 
4921 CGGCAAACAA ACCACCGCTG GTAGCGGTGG TTTTTTTGTT TGCAAGCAGC AGATTACGCG 
4981 CAGAAAAAAA GGATCTCAAG AAGATCCTTT GATCTTTTCT ACGGGGTCTG ACGCTCAGTG 
5041 GAACGAAAAC TCACGTTAAG GGATTTTGGT CATGAGATTA TCAAAAAGGA TCTTCACCTA 
5101 GATCCTTTTA AATTAAAAAT GAAGTTTTAA ATCAATCTAA AGTATATATG AGTAAACTTG 
5161 GTCTGACAGT TACCAATGCT TAATCAGTGA GGCACCTATC TCAGCGATCT GTCTATTTCG 
5221 TTCATCCATA GTTGCCTGAC TCCCCGTCGT GTAGATAACT ACGATACGGG AGGGCTTACC 
5281 ATCTGGCCCC AGTGCTGCAA TGATACCGCG AGACCCACGC TCACCGGCTC CAGATTTATC 
5341 AGCAATAAAC CAGCCAGCCG GAAGGGCCGA GCGCAGAAGT GGTCCTGCAA CTTTATCCGC 
5401 CTCCATCCAG TCTATTAATT GTTGCCGGGA AGCTAGAGTA AGTAGTTCGC CAGTTAATAG 
5461 TTTGCGCAAC GTTGTTGCCA TTGCTACAGG CATCGTGGTG TCACGCTCGT CGTTTGGTAT 
5521 GGCTTCATTC AGCTCCGGTT CCCAACGATC AAGGCGAGTT ACATGATCCC CCATGTTGTG 
5581 CAAAAAAGCG GTTAGCTCCT TCGGTCCTCC GATCGTTGTC AGAAGTAAGT TGGCCGCAGT 
5641 GTTATCACTC ATGGTTATGG CAGCACTGCA TAATTCTCTT ACTGTCATGC CATCCGTAAG 
5701 ATGCTTTTCT GTGACTGGTG AGTACTCAAC CAAGTCATTC TGAGAATAGT GTATGCGGCG 
5761 ACCGAGTTGC TCTTGCCCGG CGTCAATACG GGATAATACC GCGCCACATA GCAGAACTTT 
5821 AAAAGTGCTC ATCATTGGAA AACGTTCTTC GGGGCGAAAA CTCTCAAGGA TCTTACCGCT 
5881 GTTGAGATCC AGTTCGATGT AACCCACTCG TGCACCCAAC TGATCTTCAG CATCTTTTAC 
5941 TTTCACCAGC GTTTCTGGGT GAGCAAAAAC AGGAAGGCAA AATGCCGCAA AAAAGGGAAT 
6001 AAGGGCGACA CGGAAATGTT GAATACTCAT ACTCTTCCTT TTTCAATATT ATTGAAGCAT 
6061 TTATCAGGGT TATTGTCTCA TGAGCGGATA CATATTTGAA TGTATTTAGA AAAATAAACA 




Alk1-V5 plasmid was generated by gateway cloning of pDONR223-ACVRL1(Alk1) (a 
gift from William Hahn & David Root, Addgene plasmid # 23873) and pEF-DEST51 
(Thermo) vectors using LR Clonase enzyme mix (Thermo). Plasmid was transformed 
into DH5α and plated on LB-agar plus ampicillin for single colony selection, sequencing, 
and plasmid purification. HA-tagged Alk2, Alk3 and Alk6 plasmids were a gift from 
Aristidis Moustakas (Addgene plasmid # 80870, 80873, 80882). 
ALK1-V5 Sequencing Data: Sequenced using T7-forward primers (1051 bp) 
ORIGIN 
        1 NNNNNNNNNN NNGCTTGNTN NNCAAGTTTG TANAAAAAAG TTGGCATGAC CTTGGGCTCC 
       61 CCCAGGAAAG GCCTTCTGAT GCTGCTGATG GCCTTGGTGA CCCAGGGAGA CCCTGTGAAG 
      121 CCGTCTCGGG GCCCGCTGGT GACCTGCACG TGTGAGAGCC CACATTGCAA GGGGCCTACC 
      181 TGCCGGGGGG CCTGGTGCAC AGTAGTGCTG GTGCGGGAGG AGGGGAGGCA CCCCCAGGAA 
      241 CATCGGGGCT GCGGGAACTT GCACAGGGAG CTCTGCAGGG GGCGCCCCAC CGAGTTCGTC 
      301 AACCACTACT GCTGCGACAG CCACCTCTGC AACCACAACG TGTCCCTGGT GCTGGAGGCC 
      361 ACCCAACCTC CTTCGGAGCA GCCGGGAACA GATGGCCAGC TGGCCCTGAT CCTGGGCCCC 
      421 GTGCTGGCCT TGCTGGCCCT GGTGGCCCTG GGTGTCCTGG GCCTGTGGCA TGTCCGACGG 
      481 AGGCAGGAGA AGCAGCGTGG CCTGCACAGC GAGCTGGGAG AGTCCAGTCT CATCCTGAAA 
      541 GCATCTGAGC AGGGCGACAG CATGTTGGGG GACCTCCTGG ACAGTGACTG CACCACAGGG 
      601 AGTGGCTCAG GGCTCCCCTT CCTGGTGCAG AGGACAGTGG CACGGCAGGT TGCCTTGGTG 
      661 GAGTGTGTGG GAAAAGGCCG CTATGGCGAA GTGTGGCGGG GCTTGTGGCA CGGTGAGAGT 
      721 GTGGCCGTCA AGATCTTCTC CTCGAGGGAT GAACAGTCCT GGTTCCGGGA GACTGAGATC 
      781 TATAACACAG TGTTGCTCAG ACACGACAAC ATCCTAGGCT TCATCGCCTC AGACATGACC 
      841 TCCCGCAACT CGAGCACGCA GCTGTGGCTC ATCACGCACT ACCACGAGCA CGGCTCCCTC 
      901 TACGACTTTC TGCAGAGACA GACGCTGGAG CCCCATCTGG CTCTGAGGCT AGCTGTGTCC 
      961 GCGGCATGCG GCCTGGCGCA CCTGCACGTG GAGATCTTCG GTACACAGGG CAAACCAGCC 
     1021 ATTGCCCACC GCGACTTCAA GAGCCGCAAT G 
 
ALK Receptor Pulldowns using FKBP12-SNAP 
FKBP12-SNAP (5 μg) and tagged ALK receptor plasmids (5 μg) were co-transfected into 
Hek293T cells using SuperFect and supplied protocol. After 48 hours, cells were treated 
with DMSO (0.1%) or 1 μM FKVP for 30 min. After 1 hour, cells were lysed in vessel 
with 1mL lysis buffer (150mM NaCl, 50mM Tris-HCl, 0.1% Trition-100, 5% glycerol, 
protease and phosphatase inhibitors) and plate scraper. Lysate was transferred to 2mL 
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eppendorf and rotated at 4C for 20min. Lysates were centrifuged at 14000g for 10min, 
and ~1mL supernatant was transferred to a new tube with 200nM drug or 0.2% DMSO. 
20uL input was taken and mixed with 20uL 2x loading buffer before boiling. Each lysate 
sample was then mixed with 250uL of SNAP buffer (lysis buffer + 5mM DTT) 
containing 40μL of magnetic SNAP-capture beads (New England Bio) and rotated at 4°C 
for 1 hour. Beads were washed 3 times with 1mL lysis buffer before boiling in 100μL 2X 
loading buffer. Boiled lysates were vortexed and centrifuged, lysate (~90μL) was 
carefully removed from beads and used for western blotting. 
The same method was used for calcineurin-FK506 and mTOR-rapamycin pull-downs 
after transfection of 10ug FKBP12-SNAP cDNA only. 
 
FKBP Knockout Lines 
Jurkat T and HEK293T cells were transfected as previously described with all-in-one 
CRISPR/Cas9 (mCherry tagged) plasmids (Genecopeia) containing guide-RNAs for 
FKBP12 (HCP267023-CG01-3-B), FKBP51 (HCP257374-CG01-3-B), or FKBP52 
(HCP205551-CG01-3-B). After 48 hours, cells were sorted for mCherry fluorescence 
(650nm laser) into 96-well plates (1 cell/well). After 2 weeks of culture, single clones 






BMP and NFAT Pathway Reporters 
Jurkat T cells transfected with BRE-Luc were split into a 96-well plate (80 µL/well of 
0.5x106 cells/mL)) and treated with previously stated compounds/proteins (20 μL of 5X 
stock in RPMI, 0.5% DMSO) for 18 h. rBMP-4 and rTGF-β1 (R&D) were used as 
positive and negative controls, respectively. Plates were centrifuged at 3000 rpm for 
10min, then carefully aspirated. Cells were re-suspended in 100 μL lysis buffer (per well) 
and placed on a plate-shaker for 30 min. An aliquot of 80 μL of lysate was transferred to 
a white-walled 96-well plate, and luminescence was recorded 2 seconds after automated 
injection of luciferase substrate. Luminescence values were background subtracted (lysis 
buffer + substrate) and normalized to DMSO control values. 
FKBP12KO Jurkat T cells transfected with FKBP12-SNAP plasmid were selected with 
1200 µg/mL G418 for seven days before use in BRE-Luc assays. 
 
FKVP Synthesis and Formulation for Animal Studies 
To a solution of FK506 (100 mg, 0.120 mmol) and 40 mol% Zhan1b catalyst 
RuCl2[C21H26N2][C12H17NO3S], in 3 mL anhydrous DCE was added 4-vinylpyridine 
(14.2 µL, 0.132 mmol). The mixture was stirred for 30 s before microwave irradiation at 
120°C for 20 min. The mixture was then purified using flash chromatography (0-25% 
MeOH in DCM), preparative-TLC (9:1 DCM:MeOH), and reverse-phase HPLC (45-85% 
ACN in H2O). Conversion=25%, Purified Yield=8%.  1H-NMR experiments (Fig 2.16) 
were used to confirm the new compound was >99% pure. Product was characterized 
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using High-Resolution MS (Fig. 2.6) and 1H-NMR (Fig 2.16), then dissolved into DMSO 
or used in formulation for animal experiments.  
For animal experiments, FKVP powder was dissolved into 80% EtOH/20% Cremophor 
RH60 solution at 5mg/mL. This stock was diluted 1:50 into saline before subcutaneous 
injection. 
 
Declaration of Ethical Animal Care and Use 
Goto-Kakizaki (GK) type-2 diabetic rats obtained from Charles River (Boston, MA) were 
housed in a pathogen-free facility and cared for according to NIH guidelines and a 
protocol approved by the Johns Hopkins University Animal Care and Use Committee 
(ACUC). Both male and female GK rats at age of 4-5 months were used in this study.  
 
In vivo Excisional Wound Model 
Full-thickness wounds were created in the dorsal skin of rats with a sterile disposable 
biopsy punch (8 mm in diameter). The animals were injected subcutaneously with saline, 
AMD3100 (1mg/kg) plus FK506 (0.1mg/kg) or AMD3100 (1mg/kg) plus FKVP 
(0.1mg/kg) immediately after wounding and every other day until complete healing, 
defined as complete re-epithelialization of the wound area. For assessing the role of BMP 
signaling, animals were injected intraperitoneally (i.p.) with LDN-193189 (2mg/kg/day) 
in addition to standard saline or AF treatment. Wounds were evaluated daily according to 




Cut sections of 5 µm were prepared from frozen tissue for immunohistochemistry 
staining. Frozen sections were fixed with acetone at −20 °C for 10 min and dried for 1 h 
at room temperature. After inactivation of endogenous peroxidase and blocking of 
nonspecific antibody binding, the specimens were incubated with anti-CD133 (1:300, 
ab19898; Abcam) at 4 °C overnight. The tissue sections were then subsequently 
incubated with biotin-conjugated goat anti-rabbit IgG (1:200, #14708S Cell Signaling, 
Danvers, MA) for 30 minutes at room temperature. The VectaStain Elite ABC kit (HRP) 
(Vector Laboratories, Burlingame, CA) was used to increase the sensitivity of the 
staining. Diaminobenzidine tetrahydrochloride (5 min, D4293, Sigma-Aldrich, St. Louis, 
MO) was used as the chromogen, and Mayer’s Hematoxylin (30 s, Dako, S3309) was 
used for counterstaining.  
Statistics 
The one-way analysis of variance (ANOVA) was used to determine the statistically 
difference in wound healing among AF, AF+LDN, Saline and S+LDN groups or between 
AF, AV and Saline groups when comparing days of wound healing. Bonferroni-Holm 








In this study, we investigated the mechanism by which FK506 accelerated WH 
when used in combination with AMD3100. Using FKVP, a non-immunosuppressive 
analog of FK506, we ruled out calcineurin as a mediator of both WH accelleration, 
raising the possibility that FKBPs are the primary target for both effects. Moreover, we 
demonstrated that macrocyclic FKBP ligands activate BMP signaling by relieving the 
inhibition of BMPR1 by endogenous FKBP12. We show that FKBP12 plays an essential 
role in the BMP signaling pathway, an effect that can be mediated without calcineurin 
inhibition through the use of non-immunosupressive FK506 analogs. We found that BMP 
receptor signaling is required for wound healing enhancement by FK506, and that 
blocking this activation results in fewer numbers of stem cells recruited to the wound 
area. BMP signalling may maniuplate several cell types in the wound healing mechanism, 
such as chemotaxis of stem cells or endothelial adhesion of mobilized cells in the 





Figure 3.32: Mechanistic overview of enhanced healing by FKVP and AMD3100. 
AMD3100 releases CD133+ stem cells into circulation, where FKVP-mediated BMP 
activation influences recruitment to wounded tissues. Systemic inhibition of FKBP12 by 
FKVP allows for BMP-related gene expression in both mobilized stem/progenitor cells 
and the endothelium without affecting the necessary immune responses to wounding. 
 
FKBP12, a founding member of the FKBP superfamily, has been shown to 
possess multiple cellular and physiological functions in addition to its role in mediating 
inhibition of calcineurin and T cell activation by FK506. The association with, and 
inhibition by FKBP12 adds another layer of BMPR1 kinase regulation. That relieving 
FKBP12 inhibition by FK506 or FKVP is sufficient to activate the ID-1luciferase 
reporter gene suggests that there is a basal level of activity of BMPR that is normally 
suppressed by FKBP12 and relief of this inhibition leads to significant, albeit moderate, 
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activation of the signaling pathway in comparison to BMP-4  binding. Thus, BMPR may 
exist in three distinc activation states, upon release of FKBP12 inhibition, upon BMP 
binding and both. Our results revealed that the partial activation of BMP 
pharmacologically with FK506 or FKVP is sufficient to accelerate wound healing in 
combination with AMD3100. It remains to be seen whether that activation state is also 
achievable under physiological stimulation, and is involved in regulation of healing in 
vivo.  
Type 2 BMP receptors are reported to constitutively phosphorylate the GS 
domain of type 1 receptors (ALKs). FKBP12 is believed to inhibit random activation of 
ALKs by binding to residues in the GS domain (Chaikuad et al., 2012). Our results 
indicated that this association is competed by FKVP for all BMP-specific ALKs. We 
showed that loss of FKBP12 results in elevated basal phosphorylation of SMAD1/5, 
suggesting a partially activated state of ALKs in the absence of its endogenous 
intracellular inhibitor FKBP12. The additive increase in ID-1 reporter stimulation from 
concommitant FKVP and rBMP treatment is also consistent the three activation states of 
BMPR1.  Futhermore, addition of the BMP inhibitor noggin did not prevent ID-1 reporter 
stimulation by FKVP, suggesting that the regulation of BMPR by endogenous FKBP12 is 
independent of BMP protein-receptor binding.  
Several solved crystal structures of both BMP and TGF-β ligands and receptors in 
complex show key structural differences (Mueller et al., 2015). For example, the TGFβ-
TGFBR1-TGFBR2 complex is reported to involve type1-type2 receptor interactions, a 
feature absent in BMPR-ligand complexes. These specific interactions are believed to be 
a consequence of ligand binding, as TGFBR1 shifts its orientation to contact the bound 
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ligand. This added layer of regulation may explain discrepancies in TGF-β reporter 
activation by FK506 when compared to BMP, as FKBP12 dissociation may be a second 
added layer of protection in the TGF-β pathway.  
Inhibition of calcineurin by FK506 has been shown to be responsible for both its 
potent immunosuppressive activity and a number of its side effects including 
nephrotoxicity and neurotoxicity (Bechstein et al., 2000, Naesens et al., 2009). By 
placing a molecular “bump” on the calcineurin-interacting effector domain of FK506, the 
resultant FKVP lost its immunosuppressive activity as judged by the NFAT reporter gene 
assay (Figure 2.6). In comparision to calcineurin, the loss of function of FKBP12 and 
other members seems to have much fewer and less drastic impact on both yeast and 
mammals. Aside from BMP receptors, FKBP12 has been reported to modulate calcium 
flux in inositol 1,4,5-trisphosphate (IP3) and ryanodine receptors (Cameron et al., 1995; 
Jayaraman et al., 1992), suggesting FK506 may affect vascular or cardiac smooth muscle 
contractility. However, calcineurin inhibition alone has been recognized as a key 
potentiator of hypertension (Hoorn et al., 2012). As such, non-immunosuppressive FKBP 
ligands should have fewer side effects, resulting in safer and more selective 
pharmacological BMP agonists. Moreover, FKBP52 inhibition by FK506 has been shown 
to augment nerve regeneration (Gold, B.G., 1999; Gold, B.G. et al, 1999), suggesting the 
effect may synergize with FKBP12–mediated  tissue regeneration through BMP 
signalling. In addition to wound healing, FK506 has also been shown to be effective 
against pulmonary artirial hypertension and invasiveness in bladder cancer through 
activation of BMPR signaling (Spiekerkoetter et al., 2013; Shin et al., 2014). It is 
possible that FKVP and other analogs may find use in treating these conditions.  
86 
 
That FKVP is as effective in the enhancement of WH as FK506 also has important 
clinical implications due to its lack of immunosuppressive effect. In patients with a 
greater risk of infection, such as those with diabetes, treatment with FKVP will provide 
effective treatment without the risks associated with immunosupressants. This is 
higlighted in our use of Goto-Kakazaki rats for this study; a rat model that spontaneously 
develops type-2 diabetes after 3-4 months of age and suffers from many of the same 
physiological manifests that affect humans with the disease, including significantly 
impaired wound healing. By using such a model for this study, we aim to convey the 
power of this treatment and its application to clinical use. Our demonstration that FKVP 
recapitulates the WH efficacy of FK506 in the challenging rat model makes FKVP an 
attractive lead compound, and it is expected  that other non-immunosuppressive ligands 
devoid of inhibitory activity towards calcineurin similar to FKVP will possess similar 
beneficial effects. Furthermore, the synergistic activities of AMD3100 and FKVP 
demonstrate a regenerative therapy that could potentially be applied to several other types 
of tissue damage. Beyond WH, our lab has shown improved liver regeneration after 
partial hepatectomy and AF combination treatment (Zhai et al., 2018). Thus, FKVP and 








4. Structure-Activity Relationships Highlight an Alternative Mechanism for 
Calcineurin Repulsion in Non-Immunosuppressive FK506 Analogs Generated by 
One-Step Heck Reaction*# 
*This work was completed in collaboration with Dr. Yuefan Wang. 
#YW synthesized and characterized analogs, BP performed cell-based assays 
4.1 INTRODUCTION 
In the previous chapter, a novel non-immunosuppressive FK506 analog named FKVP 
was described that retains FKBP binding and lacks calcineurin inhibition activity (Peiffer 
et al, 2019). FKVP was found to activate Bone Morphogenic Protein (BMP) signaling in 
lymphocytes and endothelial cells through inhibition FKBP12-BMPR1 interaction. 
Moreover, the combination of FKVP and AMD3100 was found to accelerate wound-
healing in diabetic rats in a BMP receptor-dependent manner.  
To conduct a structure-activity relationship study, we needed to synthesize new analogs 
of FKVP containing the pyridine core structure. In the past, we and others have relied on 
ruthenium-catalyzed cross metathesis reaction (CM) to modify the terminal alkene of 
FK506 (C40) to generate non-immunosuppressive FK506 analogs (Clemons et al, 2002). 
Unfortunately, coupling of nitrogen-containing heterocycle and aniline routinely suffer 
from low yield. This is most likely due to the nitrogen lone electron pair that competitively 
binds to the ruthenium metal center (Compain et al., 2007). Soluble ammonium salts 
(Woodward et al., 2011) displayed improved yields in CM of analogs with amines 
(Chapter 2, Fig 2.2), but not in the case of our lead compound, FKVP. 
Accounting for the issues associated with ruthenium-catalyzed coupling, we evaluated 
use of the Heck reaction to install aryl-halides at the terminal alkene. Palladium catalysts 
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used in the Heck reaction are compatible to nitrogen-containing heterocycles such as 
pyridine (Heck et al, 1972).   
We found that palladium complexes can efficiently catalyze reactions between 
aryl halides (Br or I) and the immunosuppressive drug FK506 at the terminal alkene 
position. From this novel approach, we increased the synthetic yield of FKVP over 
eight fold, and the one-step reaction allowed for fast and efficient SAR of the lead. 
Activity studies of pyridine analogs provided insights into the steric and electrostatic 
interactions beween the allyl group in the effector domain of FK506 and calcineurin, 





















The heck reaction was optimized using FKVP as a model synthesis. Various conditions 
were tested including different temperatures, base reagents, and additives reported in 
literature. The highest yield of FKVP resulted from standard conditions with an organic 
base (entry 6, Fig. 4.1). 
 
Figure 4.1 Heck synthesis optimization of FKVP synthesis. Reaction conditions and 
reagents were varied using different bases and additives. Triethylamine showed the most 
successful conversion to product (nBu = n-butyl). 
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With FKVP as the lead compound, we selected 7 nitrogen-containing heterocyclic 
halides with a pyridine core and 4 halides with substituted anilines as substrates for the 
Heck reaction. To our delight, all halide substrates were successfully coupled to FK506 
with moderate to good yields (36-78%, Fig. 4.2). 
Aryl-halide substrates displayed distinct reactivity in the Heck reaction. First, 
bromides and iodides gave similar yields. Second, electron-withdrawing groups on the 
pyridines and quinolines appeared to increase the yields (entry 4,6,7). Third, unprotected 
anilines gave the lowest yields (entry 9-11). Importantly, the unreacted FK506 starting 
material in the reaction mixture was easily separated from the more polar nitrogen-









Figure 4.2: Synthesis scheme of FK506 analogs prepared by Heck reaction and table 
of substrates. Compounds 1-11 were prepared in moderate yields using the presented 






 With FK506 analogs in hand, we assessed their effects on cell viability, BMP 
activation and NFAT activation at two concentrations. In the HUVEC cell viability assay, 
we found that quinoline analogs (5b-7b) inhibit cell proliferation at 10 µM (Fig. 4.3), while 
other compounds (1b-4b, 8b-11b) show comparable cytotoxicity to FK506. Interestingly, 
all compounds gave cell viability scores similar to others in their class (i.e. pyridine > 
aniline > quinolone). This suggests that cell viability can be affected by even small 
molecular changes at the terminal alkene.  
 
 
Figure 4.3: FK506 analogs display variable cell-viability. Cell viability after 72-hour 
analog treatment in HUVEC cells. Error bars represent standard deviation from mean for 



















 We used a BMP-response-element (BRE) pathway reporter (luciferase under the 
control of the ID1 gene promoter) (Figure 2.7) (Spiekerkoetter et al, 2013) in Jurkat 
T-cells to determine whether the new analogs were capable of activating the BMP 
signaling pathway. Initial screening of the compounds showed that most analogs had 
similar activity as FK506 or FKVP. This is somewhat expected, as we have 
previously shown that FKBP12 binding is necessary and sufficient for activation of 
BMP signaling (Fig. 4.4)  
 
Figure 4.4: FK506 analogs display similar BMP activation potential. All analogs 
activate a BMP pathway reporter in Jurkat cells with similar potency to FK506. Error 
bars represent standard deviation from mean for all measurements (n=3), and 




















 To determine the effect of the analogs on calcineurin, we turned to a 
PMA/ionomycin-activated Nuclear Factor of Activated T-cells (NFAT) reporter 
system (Figure 2.5) in Jurkat T cells (luciferase under the control of the IL-2 
promoter) (Clemons et al., 2002) (Fig. 4.5). Two analogs (2b, 3b) did not cause 
significant inhibition of the NFAT-Luciferase reporter at concentrations up to 10 
µM, similar to FKVP (1b). Surprisingly, most other analogs showed either partial or 
nearly complete inhibition of the NFAT reporter at 1 µM (Fig. 4.5). It is noteworthy 
that some of the immunosuppressive analogs, including 5b, 6b and 7b, have bulkier 
substituents than 2b and 3b due to the presence of a fused aromatic ring. How those 
bulkier groups are accommodated at the binding site of calcineurin remains to be 
determined.  
 
Figure 4.5: FK506 analogs display variable immunosuppressive qualities. Derivatives 


















represent standard deviation from mean for all measurements (n=3), and 
absorbance/luminescence values were normalized to DMSO treated cells. 
 We determined EC50 values of three non-immunosuppressive analogs (1b-3b) in 
the BMP luciferase assay. All 3 analogs were found to be slightly more potent than FK506 
(Fig. 4.6), likely attributable to increased solubility due the more polar pyridine 
substituents. Among the three analogs, FKVP remained the most active among the group 
with an IC50 of 12.4 nM. However, compounds 2 and 3 remained similarly effective 
(insignificantly different from FKVP (p>0.05), suggesting that they could be further tested 
for in vivo PK enhancement.  
 
Figure 4.6: Dose-response curves for BMP reporter activation by three non-
immunosuppressive analogs (1b, 2b, and 3b) and FK506. FKVP and amine-substituted 
pyridine analogs show potent BMP activation after dose-response treatments in BRE-luc 


















4.3 MATERIALS AND METHODS 
General Information 
Normal phase disposable flash columns RediSep®Rf for flash chromatography were 
purchased from Teledyne Isco, Inc. Solvent was used extra dry over molecular sieve, 
stabilized, AcroSeal®. Yields refer to chromatographically homogeneous materials. 
Reactions were monitored by mass spectrometry provided by Agilent 6120 Quadrupole 
LC/MS. PLC Silica gel 60 F254, 1mm supplied by EMD Millipore using UV light as 
visualizing agent. 
1H-NMR was recorded on Bruker Avance III 500 MHz NMR spectrometer. TMS was 
used as internal standard for 1H-NMR (0 ppm). High-resolution mass spectra (HRMS) 
were recorded on Waters Synapt G2-Si mass spectrometer using ESI (electrospray 
ionization). FK-506 (Tacrolimus) was purchased from Biotang Inc. Zhan-1b catalyst, 
palladium acetate and tris(o-tolyl)phosphine were purchased from Aldrich.  
 
Cell Culture and Transfections 
Jurkat (E6.1, ATCC) cells were cultured in RPMI with 10% FBS and 1.5% PennStrep. 
Jurkat cells (1 x 106) were transfected with 10 μg of BRE-Luciferase (kindly provided by 
Martine Roussel & Peter ten Dijke) or NFAT-Luciferase cDNA (Promega) by 
electroporation (BioRad, square-wave, 250V, 950 μF) in 400 μL serum/antibiotic free 
RPMI with 0.5% DMSO. Thirty minutes after transfection, cells were transferred to 
complete RPMI and rested overnight. Before plating, cells were re-suspended in fresh 
media and diluted to 0.5x106 cells/mL. 
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HUVEC cells were cultured in Lonza Endothelial cell Growth Medium (EGM-2) and 
used between passages 3 and 7. All cells were grown and assayed at 37°C with 5% added 
CO2. 
 
Cell Viability Assays 
HUVEC cells were plated at 1000 cells/well in 180 μL growth media before addition of 
20 μL of 10X drug/protein stock. After 72-hour treatment, 22 μL of a resazurin sodium 
salt solution (0.1 mg/mL stock in water) was added to each well and allowed to incubate 
at 37°C. The metabolic conversion of resazurin dye was monitored by absorbance at 570 
nm after 6 hours. After background subtraction (media only + dye), absorbance values 
were left as arbitrary absorbance units or normalized to those obtained by DMSO. 
 
BMP and NFAT Reporters 
Jurkat cells used for each experiment were transfected at the same time and cultured 
together overnight until plating and treatment the following day. 
Jurkat T cells transfected with BRE-Luc were split into a 96-well plate (80 μL/well of 
0.5x106 cells/mL)) and treated with previously stated compounds (20 μL of 5X stock in 
RPMI, 0.5% DMSO) for 18 hours. Cells were lysed and measured for luminescence as 
previously reported (Peiffer et al., 2018). Luminescence values were background 
subtracted (lysis buffer + substrate) and normalized to DMSO control values. 
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Jurkat T cells transfected with NFAT-Luc were split into a 96-well plate (80 μL/well of 
0.5x106 cells/mL) and treated with indicated compounds (20 μL of 5X stock in RPMI, 
0.5% DMSO) 30 min before activation with PMA/Ionomycin (40 nM/1 μM). After 6 
hours, wells were lysed and measured for luminescence as previously stated (Peiffer et 
al., 2019). FK506 served as positive control while DMSO and non-activated wells gave 
negative and background control values, respectively. 
 
EC50 Determinations 
Calculations were performed using GraphPad Prism 6. Curves were fit using non-linear, 
log(agonist) vs. response (three parameters). 95% confidence intervals of EC50 values are 
reported below. 
 
Optimization of Heck reaction conditions: 
To a mixture of FK-506  (0.0500 mmol, 40 mg, 1.0 equiv), Pd(OAc)2(0.00500 mmol, 1.1 
mg, 0.10 equiv), P(o-tol)3(0.0100 mmol, 3.0 mg, 0.20 equiv), base and additives in flame-
dried 10 mL-Schlenk tube, dry DMF(1.0 mL) was added under Ar balloon protection, 







General procedure for the Heck reaction 
To a mixture of FK-506 (0.0500 mmol, 40 mg, 1.0 equiv), aryl halides (2.0 equiv) and 
Pd(OAc)2(0.00500 mmol, 1.1 mg, 0.10 equiv) and P(o-tol)3(0.0100 mmol, 3.0 mg, 0.20 
equiv) in flame-dried 10 mL-Schlenk tube, dry DMF(1.0 mL) and Et3N(0.10 mL) dried 
over K2CO3 was added under an inert atmosphere of Argon, and the mixture was stirred 
at 100 C. When the reaction was complete, (determined by mass spectrometry) the crude 
mixture was cooled to RT and purified by flash chromatography (gradient elution using  
dichloromethane and methanol) to give the corresponding product. If necessary, 
preparative TLC was used to separate byproducts from base-epimerization of FK506. 
 
1b: 1H-NMR (500MHz, CDCl3) 8.51 (br s, 
2H), 7.18 (br s, 2H), 6.40-6.32 (m, 2H), 5.33 
and 5.18 (rotamers, d, J = 1.05, 1H), 5.11-
5.05 (m, 2H), 4.99 and 4.65 (rotamers, d, J = 
4.55, 1H), 4.71 and 4.24 (rotamers, s, 1H), 
4.43 and 3.72 (rotamers, d, J = 12.5, 1H), 
3.94-3.84 (m, 1H), 3.72-3.61 (m, 2H), 3.44-
3.35 (m, 9H), 3.34-3.29 (m, 3H), 3.06-2.96 (m,2H), 2.84-2.61 (m,3H), 2.33-2.25 (m,2H), 
2.21-1.96 (m, 7H), 1.95-1.85 (m, 2H), 1.72-1.44 (m, 18H), 1.03-0.81 (m, 11H); HRMS 



























 The structure of the complex of FKBP12-FK506-calcineurin has been previously 
determined by X-ray crystallography (Griffith et al., 1995, Kissinger et al., 1995). In this 
complex, the terminal alkene of FK-506 fits into a binding pocket in calcineurin formed by 
hydrophobic amino acids (Fig. 4.7a). When modeled in place of FK506, the pyridine 
moiety in FKVP (1b) has a steric clash with residue M118 of calcineurin (Fig. 4.7b), which 
explains the elimination of calcineurin binding by analogs 1b-3b. However, how other 
analogs bearing bulkier substituents than FKVP at the same position remain 
immunosuppressive cannot be explained by the structure.  
 
Figure 4.7: Modeling of FKVP at the FK506-binding site of calcineurin. (a) Expanded 





After surveying pKa values of the newly-added moeities (SciFinder, Table 4.1), 
we noticed that compounds with higher pKa values (1b,2b,3b,5b) showed less 
calcineurin inhibition. Conversely, those with a lower pKa caused by electron-
withdrawing groups were all immunosuppressive at 1 µM (4b,6b,7b). The pKa value of 
aniline (9b-11b) is lower than pyridine (1b), which may also explain its retention of 
inhibitory activity for calcineurin. 
 












 These observations suggest that the formation of positively charged pyridinium 
appendage at the terminal alkene of FK506 plays a more important role in disrupting the 
interaction between the terminal alkene of FK506 and the hydrophobic pocket in 
calcineurin. These observations present an alternative and complementary mechanism for 
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the loss of calcineurin inhibition in non-immunosuppressive FK506 analogs, which in the 
past has been rationalized by a large molecular “bump” to sterically hinder calcineurin 
binding (Clemons et al., 2002). It is likely that the same binding pocket in calcineurin has 
significant conformational flexibility to accommodate non-charged bulky aromatic rings 
such as those present in 4b, 6b and 7b.  
In summary, we have developed a one-step synthesis of FK506 analogs containing 
nitrogen bases using the Heck reaction. We identified three non-immunosuppressive 
analogs with higher potency in activating the BMP signaling pathway. We found that a key 
element in disrupting FK506-calcineurin interaction is through electrostatic rather than 
steric alteration. Given the role of BMP signaling in wound healing and tissue regeneration, 
the newly developed synthetic route to FKVP and analogs will facilitate the 
pharmacokinetic development of non-immunosuppressive analogs of FK506 for 










Figure 4.8: Proposed workflow for identification of clinic-ready FK506 analogs 
for pharmacological BMP activation. (1) A rationally designed FK506 analog 
library is screened using a high-throughput compatible, three-assay system. (2) Top 
performing candidates are then validated in vitro through EC50 analysis in the BMP-
reporter assay. (3) Validated compounds are moved into pre-clinical animal studies 
to determine inter-analog differences in ADME (absorption, distribution, 






5. INTERACTOME STUDIES AND ENHANCED BMP ACTIVATION 
THROUGH CHEMICALLY-INDUCIBLE FKBP12 DEGRADATION 
5.1 INTRODUCTION 
The recent resurgence of thalidomide in chemical biology has opened a new field 
in the small-molecule therapeutic landscape. By conjugating thalidomide to other small 
molecules, scientists have been able to selectively degrade target proteins for several 
applications (Figure 5.1) (Neklesa et al, 2017). 
 
Figure 5.1: Chemically induced proteasomal degradation of proteins of interest 
(POI).  A fusion molecule induces dimerization of both POI and the E3 ligase complex. 
Subsequent proximity to the E2 ligase promotes ubiquitination of POI, causing 
proteasomal recognition and degradation (adapted from Yesbolatova and Kanemaki, 
2018). 
 
Thalidomide was discovered as a modulator of E3 ligase-mediated ubiquitination 
of target proteins for degradation. Specifically, thalidomide and its derivatives was shown 
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to interact with the substrate recognition adaptor protein, cereblon (CRBN). It was first 
shown that conjugation of thalidomide to the FKBP-binder Shield-1(SLF derivative) 
caused potent CRBN-dependent degradation of FKBP12 (Figure 5.2) (Winter et al., 2015). 
This occurs through induced association of FKBP12 and CRBN, facilitating FKBP12 
ubiquitination by the E3 ligase complex and subsequent proteasomal degradation. Further 
studies showed that thalidomide conjugation could induce degradation of several proteins, 
and other E3 ligase modulators showed similar activities when conjugated (Neklesa et al, 
2017).  These discoveries spurred the creation of proteolysis targeting chimeras 
(PROTACs) for the degradation of unwanted proteins in biological systems. 
 
Figure 5.2: Chemically induced proteasomal degradation of FKBP12.  A fusion 
molecule of synthetic ligand of FKBP (SLF) and thalidomide induces dimerization of 
FKBP12 and cereblon (CRBN). Subsequent proximity to the E2 ligase promotes 
ubiquitination of FKBP12, causing proteasomal recognition and degradation (adapted from 
Yesbolatova and Kanemaki, 2018). 
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That a small-molecule could efficiently degrade FKBP12 is of great interest to our 
lab. As shown in Chapter 3, FKBP12 deletion caused increased basal SMAD1/5 
phosphorylation. We theorized that acute degradation of FKBP12 may result in a more 
sustained BMP activation, increasing potency of wound healing therapy. 
It was hypothesized that any FKBP-binding molecule would act similarly when 
conjugated to thalidomide, as Shield-1 is not an FKBP12 selective compound. To this end, 
we decided to again use FK506 as our FKBP-binding scaffold. Macrocyclic structures such 
as FK506 show increased cell-penetration and binding affinities over linear FKBP12 
binding molecules (Marinec et al., 2009), and our recent success with cross-metathesis 
presented a simple synthetic process for compound development. Testing of our 
thalidomide-conjugated FK506 analog (FKTM) revealed potent FKBP12 degradation, as 
well as concurrent degradation of fused fluorescent proteins. This raised the possibility that 
tightly associating proteins could be targeted through the same degradation mechanism. 
In this study, we employed lessons learned from synthesis and testing of FKTM to 
develop a new strategy for interactome studies in living cells. Using thalidomide 
conjugation at allosteric sites, we show that protein binding partners are also subject to 
promiscuous ubiquitination through CRBN. Therefore, relative protein abundance serves 
as a measure of its association with the thalidomide-tagged target. As a proof of concept, 
we employ this method to study both inducible (FKBP12-FK506-Calcineruin) and 






Synthesis of thalidomide-conjugated FK506 
Thalidomide-conjugated FK506 (FKTM) was designed using a 6-carbon linker 
with a terminal alkene for CM and an iodine leaving group (Fig. 5.3). Previous work in 
this area showed that small linkers (4 carbons + 1 peptide) were amenable to FKBP12 
association with CRBN (Winter et al, 2015). Synthesis of FKTM proceeded by CM 
reaction of FK506 and 6-iodohexene, followed by nucleophilic substitution by a phenol-
substituted thalidomide. HPLC purification produced a stable product that was 









Figure 5.3: Synthesis of thalidomide-conjugated FK506 (FKTM). Two step synthesis 
using cross metathesis of 6-iodohexene, followed by Sn2 substitution of iodine by phenol-









Figure 5.4: Hi-resolution mass-spectrometry profile of FKTM.  













FKTM selectively degrades FKBP12 in wild-type Jurkat cells 
We first tested the ability of FKTM to degrade FKBP12 in Jurkat cells. Western 
blotting showed that 100 nM FKTM degrades FKBP12 to the point of being undetectable 
after 24 hours, as compared with an FKBP12KO cell line (Fig. 5.5).  
 
 
Figure 5.5: FKTM effectively degrades FKBP12 in wild-type Jurkat cells. Western 
blotting shows FKBP12 is completely degraded in Jurkat cells. FKBP12KO Jurkat cells 









Further study by a colleague, Dr. Zufeng Guo, showed that FKBP12 was the only 
FKBP degraded by FKTM (Fig. 5.6). This is surprising, as nearly all FKBP proteins have 
nanomolar affinity for FK506. This effect may be due to the relatively high expression of 
FKBP12, or the mechanism of degradation by CRBN modulation. The selectivity of 
FKTM makes it an attractive candidate for BMP activation in wound healing and 
regenerative therapies, as we have previously shown isoform FKBP12 dependence in 
BMP activation (Chapter 3). 
 
 
Figure 5.6: FKTM selectively degrades FKBP12 in wild-type Jurkat cells. Western 
blotting shows only FKBP12 is degraded in Jurkat cells. HSP90 serves as loading control 




Additionally, Dr. Guo showed that FKTM-induced degradation of FKBP12 was 
competed by rapamycin and FK506 treatment, confirming that FKTM-FKBP12 binding 
was necessary for degradation (Fig. 5.7). Interestingly, synthetic ligand of FKBP (SLF) 
was incapable of competing with FKTM for degradation. This may be due to the higher 
FKBP12 affinities present in macrocyclic FKBP binders. 
 
 
Figure 5.7: FK506 and Rapamycin, but not SLF competes with FKTM for FKBP12 
degradation in Jurkat cells. Western blotting shows only the macrocyclic FKBP ligands 








FKTM potently activates BMP reporter through FKBP12 competition and 
degradation. 
 Degradation activity can also be measured by BMP reporter in Jurkat cells, as we 
have previously reported that FKBP12 knockout causes uncontrolled BMP 
activation (Figure 3.17). In the BMP reporter assay (Figure 2.7), FKTM proved to 
be the most potent BMP activator that we have tested to date, with an EC50 below 1 
nM (Fig. 5.8). This most likely occurs from a combination of FKBP12 dissociation 
(from BMP receptors) and degradation. 



























Figure 5.8: FKTM potently activates BMP reporter through FKBP12 competition 
and degradation. BMP reporter assay in Jurkat cells shows potent activation by FKTM 




FKTM degrades an FKBP12-YFP fusion protein in Hek293T cells. 
We then determined the ability of FKTM to degrade an overexpressed FKBP12-
YFP fusion protein in HEK293T cells. FKTM significantly reduced YFP fluorescence, 
which could be competed by FKVP (Fig. 5.9). Interestingly, the proteasome inhibitor 
bortezomib could not block degradation of YFP. This may be due to the low treatment 
concentration or compound degradation, but a larger dose of bortezomib could not be 
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Figure 5.9: FKTM degrades an FKBP12-YFP fusion protein in Hek293T cells. YFP 
fluorescence was measured in FKBP12-YFP transfected Hek293T cells after 24hr FKTM 
treatment. This effect was competed by FKVP, but not by bortezomib. 
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Induced degradation platform proof-of-concept design 
The finding that thalidomide conjugation could induce fusion protein degradation 
raised interesting questions. Specifically, if thalidomide can degrade one protein, could it 
degrade associated proteins in a complex?  To test this possibility, we needed to devise a 
method for allosterically tagging a protein of interest with thalidomide. This differs from 
previous reports, as compounds like PROTACs often use the active site for target protein 
binding (Neklesa et al, 2017). Fortunately, we had designed an FKBP12-SNAP construct 
for our earlier studies that could be implemented in our novel scheme. SNAP tags allow 
covalent in-cell attachment of small-molecules to proteins (Keppler et al., 2008), 
providing an excellent platform for allosteric thalidomide display. 
Our plan for this “induced degradation scheme” involves stable expression of a 
SNAP-tagged protein of interest. When the “induced degradation ligand” is added, the 
guanine substrate will be displaced by the SNAP tag, displaying a covalently-linked 
thalidomide molecule for targeted degradation (Fig. 5.10). Our hypothesis is that if 
another protein complexes with the protein of interest, they too may be targeted for 
degradation by recruitment of promiscuous E3 ligase complexes. As a proof-of-concept, 








Figure 5.10: Induced degradation platform design. In this scheme, an FKBP12-SNAP 
fusion protein will be stably expressed in cells. Upon IDL ligand entry to the cell, it 
covalently binds to the SNAP tag and displays thalidomide, a ligand for the E3 ligase 
adaptor protein, cereblon (CRBN). The E3 complex then ubiquitinates FKBP12, along with 
induced (FKBP12:FK506:Calcineurin) and naturally associating (FKBP12:ALK receptor) 
proteins. This system provides an in-cell assay for interactome studies, and could easily be 
streamlined by high-throughput mass-spectrometry. 
 
Synthesis scheme of IDL ligand for SNAP-dependent degradation 
In our first attempt to synthesize IDL, we used published methods for obtaining o-
benzyl protected guanine paired with synthetic methods used for obtaining FKTM (Fig 





Figure 5.11: Synthesis scheme of IDL ligand. IDL ligand was generated through NMP-
activated substitution of 2-amino-6-chloropurine with 4-iodobenzylalcohol, followed by 








IDL ligand activates the BMP pathway reporter through FKBP12 degradation. 
We had found that the fastest way to test compounds for FKBP12 degradation was 
to use the BMP pathway reporter. To accomplish this, we compared IDL-induced BMP 
reporter activation in WT and FKBP12KO Jurkat cells after transfection with FKBP12-
SNAP. Results showed that only cells with FKBP12-SNAP were sensitive to IDL treatment 
(Fig. 5.12). This suggests that both the SNAP and thalidomide portions of the molecule 
performed correctly, causing targeted degradation of FKBP12-SNAP and therefore BMP 
reporter activation. 
   
Figure 5.12: IDL ligand activates the BMP pathway reporter through FKBP12 
degradation. IDL ligand shows dose-dependent activation of the BMP reporter in 


















for all measurements (n=3), and absorbance/luminescence values were normalized to 
DMSO treated cells. 
 
IDL ligand degrades the FKBP12-interacting protein calcineurin in the presence of 
FK506 
To continue our proof-of-concept study, we explored FKBP12 degradation in the 
context of the FKBP12-calcineurin complex. Western blotting showed IDL potently 
degraded the FKBP12-SNAP fusion protein in HEK293T cells (Fig. 5.13). Interestingly, 
there was a clear reduction in calcineurin protein abundance when IDL was combined with 
FK506. This gives strong evidence that proteins could be targeted for degradation through 
association with the tagged protein. Conversely, mTOR was not reduced by combined IDL 
and rapamycin treatment (data not shown). This outcome is rationalized though the large 





Figure 5.13: IDL ligand degrades the FKBP12-interacting protein calcineurin in the 
presence of FK506. Western blotting shows IDL ligand degrades calcineurin and 











IDL ligand degrades the natural FKBP12-interacting protein Alk1 
To continue our study, we investigated degradation of endogenously associating 
proteins. In this context, we used FKBP12-ALK1 as a model for proteins that naturally 
associate (Figure 3.20). In Jurkat cells stably transfected with FKBP12-SNAP, we found 
that ALK1 was degraded in a dose dependent fashion by IDL (Fig. 5.14). Although 
degradation was not competed by FK506 (data not shown), it may help to explain the 
accompanying lack of complete reversal in fluorescence experiments. This is most likely 
because ubiquitination of target proteins is non-reversible in this system. 
 
 
Figure 5.14: IDL ligand degrades the natural FKBP12-interacting protein Alk1. 






5.3 MATERIALS AND METHODS 
FKBP12KO cells were generated as previously described (Chapter 3, Fig. 3.15) 
 
Cell Culture and Transfections 
Jurkat (E6.1, ATCC) cells were cultured in RPMI with 10% FBS and 1.5% PennStrep. 
Jurkat cells (1 x 106 ) were transfected with 10 μg of BRE-Luciferase (kindly provided by 
Martine Roussel & Peter ten Dijke) or NFAT-Luciferase cDNA (Promega) by 
electroporation (BioRad, square-wave, 250V, 950 μF) in 400 μL serum/antibiotic free 
RPMI with 0.5% DMSO. Thirty minutes after transfection, cells were transferred to 
complete RPMI and rested overnight. Before plating, cells were re-suspended in fresh 
media and diluted to 0.5x106 cells/mL. HEK293T cells were cultured in DMEM with 
10% FBS, 1% PennStrep, and 500 µg/mL G418 (Corning). Cells were transfected using 
SuperFect reagent and supplied transfection protocols. All cells were cultured at 37 °C 
with 5% CO2. 
 
Western Blot 
Jurkat T cells were collected by centrifugation (300g, 5 min), washed with PBS, and 
lysed in RIPA buffer containing protease and phosphatase inhibitors (Cell Signaling) 
with sonication. Lysates were normalized using DC assay (BioRad) and run on SDS-
PAGE gels. Proteins were transferred to nitrocellulose membranes overnight at 100mA. 
After blocking with 5% milk in TBS-T for 20 min, membranes were incubated overnight 
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at 4°C with primary antibodies (Table 3.1). After washing three times with TBS-T, 
membranes were incubated with secondary antibody (Table 3.1) for 1 hour. After 3 
additional washes, blots were visualized using SynGene, either using ECL substrate 
(Thermo) or laser excitation and filter (647 nm). 
 
Fluorescent Protein Degradation 
FKBP12KO HEK293T cells were transfected with YFP-FKBP12 as previously described 
(Chapter 3). After 24 hours, cells were split into 96-well plates and treated with FKTM 
for an additional 24 hours. Afterwards, cells were aspirated and lysed in luciferase lysis 
buffer before measurement on a plate reader. 
 
IDL Ligand Synthesis 
N-Methyl-2-pyrrolidone (NMP)-Protected Guanine (5): Chloro-pyrimidine (4) (0.5g) 
was dissolved in DMF at 50 °C, and cooled to rt before addition of 1.4 mL N-
methylpyrrolidine. The final mixture was stirred overnight. Product (440 mg) was 
obtained after vacuum filtration and washing with ethyl acetate. 
 
4-Iodo-O-benzyl guanine (6): Dry DMF (1mL) was added to 22 mg NaH at 0°C under 
argon. 4-Iodo-benzyl alcohol was dissolved in 2 mL dry DMF and added dropwise to the 
NaH solution under argon. After 15 mins, 10 mg DMAP and 100 mg NMP-protected 
guanine was dissolved in 2 mL dry DMF, and added slowly to the NaH solution. The 
mixture was stirred and allowed to come to RT and react for 2 hours before quenching 
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with 2 mL H2O. Ethyl acetate (3 x 10 mL) was used to extract the compound and dried 
under vacuum. 
 
Hexene-conjugated thalidomide (7): Phenol-thalidomide (40mg, provided by Dr. 
Wukun Liu) was dissolved in 2 mL DMF and stirred with 2eq. K2CO3 for 20 min at room 
temperature before addition of 60 µL 6-iodo-1-hexene. The mixture was stirred in the 
dark and monitored by TLC (10% methanol in dichloromethane). After 4 hours, the 
reaction was quenched with water (2 mL) and extracted with ethyl acetate (3 x 10 mL). 
The final product was a light-yellow solid (Mass:357 (H+), 57 mg, 90% crude yield) that 
was used without further purification.  
 
IDL Ligand (8): 4-iodo-benzyl-guanine and hexane-conjugated thalidomide were mixed 
1:1 (0.5 mmol) in 2 mL dry DMF. 5% Palladium acetate and 10% o-tolulyl phosphine 
was dissolved in 1mL dry DMF and mixed with 100 µL TEA. The mixture was stirred 
under argon overnight at 100 °C. Product was purified using flash chromatography 
(gradient elution with dichloromethane and methanol) and HPLC (semi-preparative C18 
column). 
 
Synthesis of FKTM (3) 
To 40 mg (0.05mmol) of FK506 (1) in 3 mL DCE was added 52 mg (0.25mmol) 6-iodo-
1-hexene and 7.4 mg (0.01mmol) Dichloro[1,3-bis(2,4,6-trimethylphenyl)-2-
imidazolidinylidene][[5-[(dimethylamino)sulfonyl]-2-(1-methylethoxy-
O)phenyl]methylene-C]ruthenium(II) (Zhan 1b catalyst). The vial was capped and heated 
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using microwave at 60 °C for 2.5 hours. Product was flash purified on silica to obtain a 
mixture of product (2) and FK506. Evaporated crude product (20 mg) was then dissolved 
into 5 mL DMF containing 10 mg (0.075mmol) potassium carbonate and 21 mg 
(0.075mmol) 4-hydroxythalidomide (Cas. 5054-59-1).  The mixture was stirred at room 
temperature for 48 hours before water quenching (5 mL), ethyl acetate extraction (3 x 10 
mL), and HPLC purification (semi-prep C18 column) to obtain FKTM (3). Purified yield 
= 7%. 
 
BMP and NFAT Pathway Reporters 
Jurkat T cells transfected with BRE-Luc were split into a 96-well plate (80 µL/well of 
0.5x106 cells/mL)) and treated with IDL (20 μL of 5X stock in RPMI, 0.5% DMSO) for 
18 h. Plates were centrifuged at 3000rpm for 10min, then carefully aspirated. Cells were 
re-suspended in 100 μL lysis buffer (per well) and placed on a plate-shaker for 30 min. 
An aliquot of 80 μL of lysate was transferred to a white-walled 96-well plate, and 
luminescence was recorded 2 seconds after automated injection of luciferase substrate. 
Luminescence values were background subtracted (lysis buffer + substrate) and 
normalized to DMSO control values. 
FKBP12KO Jurkat T cells transfected with FKBP12-SNAP plasmid were selected with 






Calculations were performed using GraphPad Prism 6. Curves were fit using non-linear, 




















The selective degradation activity displayed by FKTM has revealed a previously 
unrecognized method for BMP activation. We have previously shown that genetic 
deletion of FKBP12 promotes the same BMP signaling activation as FK506 and other 
FKBP agonists, and we now show that chemical FKBP12 degradation produces similar 
results. Degradation of FKBP12 by FKTM was found to persist after 24 hours, 
suggesting compounds like these would serve as long-acting therapeutics. Moreover, our 
finding that FKBP12 is the only isoform affected by treatment suggests decreased 
opportunity for off-target effects. FKTM presents a valuable option for pharmacological 
BMP activation currently under investigation.  
This lab has previously reported that FKBP binding molecules synergize with 
AMD3100 to accelerate wound healing in diabetic GK rats after full-thickness skin 
excision (Chapter 3), and this effect was found to be BMP-dependent. FKTM represents 
a new class of compounds that may enhance wound healing through sustained BMP 
activation. Furthermore, the increased potency of FKTM over previous BMP agonists 
suggest a lower treatment dose, and the risk of free thalidomide is rendered minimal 
through use of a stable hydrocarbon linker. Through modification of FKTM’s linker 
region, derivatives could be designed to improve stability, solubility, and degradation 
activity. 
Beyond FKTM, the discovery of degradation-by-association comes as a first in the field 
of E3 ligase hijacking by small molecules. Till now, the majority of studies involve targeted 
degradation of one protein of interest. Our findings show that in some cases, protein 
complexes can be degraded by allosteric tagging of the target protein with an E3 ligase 
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binder. This data suggests that compounds like PROTACs may non-specifically degrade 
proteins that associate at allosteric regions of the target protein.  
As a proof of concept, we used an FKBP12-SNAP construct and the IDL ligand to 
show that proteins associating with FKBP12 were degraded in a dose-dependent manner. 
To highlight its applications, we studied FKBP12 interactions that were both inducible 
(FKBP12-FK506-Calcineurin) and non-inducible (FKBP12-ALK1). We theorize that this 
platform can be extended to interactome studies of several other target proteins. 
The high-throughput applications of proteomic-mass spectrometry may soon allow us 
to simultaneously measure all proteins and their abundance in cells stably expressing a 
SNAP-tagged protein of interest. Interacting proteins could then be identified by relative 
protein abundance after IDL treatment, creating a comprehensive map of associating 
proteins in one experiment. This platform has several applications in biology and drug-
discovery, and may identify undocumented protein-protein interactions that could be 
targeted for treatment of complex diseases. 
The capabilities of this platform depend largely on the ability of E3 ligases to 
promiscuously ubiquitinate proteins and their associating partners. However, there are 
several advancements that can be made to improve this activity. Several other E3 ligases 
such as MDM2 and XIAP have been shown to degrade proteins displaying specific small 
molecules (Lai et al., 2017). Creating multiple derivatives of IDL with different E3 ligase 
modulators will allow us to target more proteins, expanding the scope of the platform. On-
chip ubiquitination of immobilized human proteins could be used to determine the 
promiscuity of these E3 ligases (Cox et al., 2015) and collected data would serve to 
correlate with in-cell effects. Moreover, by using different tagging methods such as HALO 
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tags or other covalent modifiers attached at either the C or N termini, we can account for 
steric clash with proteins that may associate. 
In sum, the discovery and development of this platform may allow us to accelerate the 
discovery of protein-protein interactions, both induced and endogenous. In the near future, 
this method could be adapted to large scale interactome screening of all human proteins, 
generating big data on in-cell protein associations that could be mined for new therapy 
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